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ABSTRACT 
 
Influenza is an acute respiratory disease causing hundreds of thousands hospitalized each year 
worldwide. Vaccination plays a major role in the prevention of influenza, but due to constant 
antigenic drift and the ever-present potential for antigenic shift of the virus and an associated 
pandemic, antiviral therapy has an important role in the management of influenza. 
 
Oseltamivir (Tamiflu®) is the ethyl ester prodrug of oseltamivir carboxylate, a potent and 
selective inhibitor of the influenza virus enzyme neuraminidase. Oseltamivir is extensively 
converted to oseltamivir carboxylate by hepatic esterases and eliminated entirely in the urine. 
Neuraminidase is a surface glycoprotein of influenza viruses that cleaves terminal sialic acids 
from carbohydrates. This enzyme is critical for viral release from infected cells, prevents virus 
aggregation and facilitates viral spread in the respiratory tract.  
 
In this thesis it was synthesized a few novel promoieties from coumarin, which could be used 
as potential amine prodrugs of oseltamivir carboxylate. Different strategies for these synthesis 
were studied and attempted. By synthesizing these prodrugs the binding to albumin might 
increase and a passive targeting effect to inflamed tissue can be obtained. Synthesizing 
different esters of cis-2-hydroxycinnamic acid as pro moiety takes advantages of the fast 
breakdown from esterases in vivo and a spontaneous lactonization which regenerates the 
coumarin unit. Since coumarin has been studied for many years, the toxicity profile is well 
known, and it is found be nontoxic. The conversion or activation of a prodrug to the parent 
drug molecule in the body is a result of enzyme mediated cleavage or pH dependent 
hydrolysis of the established prodrug linkage. The human body is rich in enzymes that are 
capable of quickly hydrolyzing these ester bonds, they are ubiquitous distributed and several 
types are found in the blood, liver, and other organs and tissues. The rate of hydrolytic 
breakdown of prodrug is also dependent of steric effects/hindrance within the pro moiety and 
the percentage of protein binding.  
 
The active metabolite oseltamivir carboxylate was hydrolyzed from oseltamivir phosphate 
under acid condition. Crystals was attempted grown from both oseltamivir phosphate and 
oseltamivir carboxylate to obtain the x-ray crystal structure. The crystals grown were needle 
shaped and very small, less then 10 µm in diameter. The needle grains had also connected 
with each other to form a continuous network. To obtain single-crystal x-ray crystallographic 
data the crystals had to be three times larger and these crystals could therefore not be used. 
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ABBREVIATIONS  
 
 
ACN   Acetonitrile 
d   Doublet 
dd   Double doublet 
dt   Double triplet   
DANA   2-deoxy-2,3-dihydro-N-acetylneuraminic acid, Neu5Ac2en 
DCM   Dichloromethane 
DCC   N,N-dicyclohexylcarbodiimide  
DMAP   N,N-dimethylpyridin-4-amine 
ε    Molar absorptivity 
eq   Molar equvivalents 
G1   HPLC method, gradient 
GS 4071   Oseltamivir carboxylate 
GS 4104   Oseltamivir 
HA   Hemagglutinin 
HPLC   High Performance Liquid Chromatography 
HSA   Human serum albumin 
I1   HPLC method, isocratic (ACN:H2O (1:9)) 
IFN   Interferon 
J   Coupling constant 
LAH   Lithium aluminum hydride 
m   Multiplet 
MeOH   Methanol 
MS   Mass spectrometry 
NA   Neuraminidase 
NAI   Neuraminidase inhibitors 
NMR   Nuclear magnetic resonance 
OTV   Oseltamivir 
OTV-C   Oseltamivir carboxylate 
 
 
   ABBREVIATIONS 
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PCC   Pyridinium chlorochromate 
s   Singlet 
ssRNA   Single-stranded RNA 
t   Triplet 
TBDMS   tert-Butyl-dimethylsilyl 
td   Triple doublet 
TEA   Triethylamine 
THF   Tetrahydrofurane 
UV   Ultra violet 
δ   Chemical shift (ppm) 
WHO   World Health Organization 
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2 INTRODUCTION 
 
2.1 EPIDEMIOLOGY AND HISTORY OF INFLUENZA 
 
Definition of influenza: 
“Influenza is a highly infectious disease, particularly attacking the respiratory system, 
transmitted by inhalation of micro droplets and causing periodic epidemics and  
pandemics [1].” 
 
Influenza is an acute respiratory disease which is caused by the influenza virus and occurs 
mostly during the winter months due to endemic viral disease. The cold, crowding of people 
and higher humidity in the winter may favor virus survival outside the host airway. The 
influenza virus usually enters the body through mucous membranes in the mouth, nose or 
eyes. Then the virus infects the upper and lower respiratory tract: the nose, sinuses, throat, 
lungs and middle ear. The typically course of influenza disease is a 1-3 day period of 
incubation, with the following symptoms which are abrupt onset of fever and chill. 
Associated symptoms of myalgia, malaise, anorexia, dry cough, headache and sore throat are 
also usual. When a person with influenza coughs or sneezes, the virus becomes airborne and 
can be inhaled by anyone nearby. Since the virus is highly contagious and transmitted by 
aerosol and contagion, it spreads rapidly. Influenza afflicts large parts of the population in 
annual epidemic outbreaks, which are unpredictable in time and severity. 
 
After the discovery of the influenza virus in 1933, research on this pathogen exploded. This 
resulted in the development of an influenza vaccine. Vaccines protects against influenza by 
stimulating an immune response in the recipients. The effect of influenza vaccine depends on 
match between the antigens contained in the vaccine and the circulating viruses. Due to rapid 
antigenic drift the vaccine composition has to be updated annually. This ensures that the viral 
strains in the vaccine are closely matched to circulating strains. In response to recognition of 
the antigenic variability of influenza, the World Health Organization (WHO) established an 
influenza surveillance program in 1947. This program operates through a network of national 
and regional centers to monitor global influenza activity. This monitoring ensures that the 
composition of the influenza vaccines are annual updated and serves as an early warning of 
new pandemic strains [2]. 
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Although vaccination now has become the primary defense for preventing influenza, there are 
several reasons for why there still is a need for development of novel, selective antiviral drugs 
for the treatment of influenza. Antigenic drift in the virus may occur after the vaccine has 
been manufactured and distributed during any influenza season, the vaccine will be less 
protective, and outbreaks can occur more easily. Also the production of a vaccine against a 
new strain of influenza virus require several months of preparation. Therefore it is likely that 
vaccine would not be available for the first wave spread of influenza virus under a pandemic 
[3]. The influenza vaccine for the season 2005-2006 is an example of mismatch between the 
composition of the vaccine and the circulating strains. The dominating virus strain circulation 
in the Norwegian population was B/Malaysia/2506/2004 while the influenza vaccine 
contained the B/Shanghai/361/2002 virus strain. Lack of effect was therefore observed and 
WHO recommended that the influenza vaccine for 2006-2007 season should contain an 
influenza B/Malaysia strain [4]. If this virus had been a more virulent one, for example a 
influenza type A virus, an epidemic would possible have developed. 
 
The WHO recommendation for vaccines to be used in the 2006-2007 season in the northern 
hemisphere should contain the following viral strains [5]: 
 an A/New Caledonia/20/99(H1N1)-like virus 
 an A/Wisconsin/67/2005 (H3N2)-like virus 
 a B/Malaysia/2506/2004-like virus 
 
The first vaccine was prepared in 1936 from inactivated influenza viruses [1]. Now, the 
influenza vaccine is available in three types, as an inactivated whole-virus vaccine, split virus 
vaccine consisting virus particles disrupted by detergent treatment and a subunit virus vaccine 
consisting essentially of hemagglutinin and neuraminidase from which other virus 
components have been removed. The influenza vaccine contains two types of influenza A 
viruses and one type of influenza B virus strains [6].  
 
Unlike the influenza vaccine, antiviral agents are not dependent of the antigenic make-up of 
the circulating viruses and they are effective in both prophylaxis and treatment. Two classes 
of influenza antivirals are now available for use, M2 inhibitors and neuraminidase inhibitors, 
each class inhibits different steps in the viral replication. Antiviral agents may be particularly 
important for pandemics, especially in the early months, when the supplies of vaccines are 
likely to be severely limited. 
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Figure 1 Classification of disease by incidence 
 
 
The history of influenza epidemics and pandemics can be traced back with some accuracy for 
the past three hundred years. After the discovery of the influenza virus, outbreaks has been 
recorded and confirmed by laboratory diagnosis. In the two centuries before this time, 
infections were identified by the known signs and symptoms of disease and the explosive 
nature of outbreaks. Originally the term influenza came from the Italian form of Latin 
influential, meaning “epidemic”, because they believed that epidemics were though to be due 
to astrological or other occult influences [7]. 
Epidemics of influenza are characterized by a high number of infected patients, occur 
suddenly without warning, and disappear after a few weeks or months. In annual epidemics  
5-15% of the population is affected. Influenza type A virus leads to epidemic outbreaks 
almost every year, whereas influenza B virus epidemics are less common. The reason for this 
is that influenza B viruses lack an animal host reservoir in addition to less frequent antigenic 
drift. According to historical sources, pandemics have appeared with intervals since ancient 
times. Historians of medicine agree that 10 pandemics have occurred within the last 300 years 
and the point of origin for all of them is suggested to be China/Russia/Asia. This indicates 
that the next pandemic also will emerge from this area and the virulent strain is likely to be 
the highly pathogenic H5N1. There are several reasons for why this area is likely to be the 
point of origin. One quarter of the worlds population lives in China and ducks, pigs and 
humans live very closely together. This increases the risk for reassortment to occur and 
pandemics to develop [8]. 
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Pandemic is a worldwide epidemic. These appear suddenly in a specific geographic area, 
spread throughout the world infecting millions and cause a large numbers of deaths. A 
pandemic is caused by a new influenza virus A subtype, the HA of which is not related to the 
influenza virus circulating immediately before the outbreak, and could therefore not have 
arisen from those viruses by mutation. 
Pandemics occur at 10-50 years intervals, and can affect up to 50 % of the population. 
According to this, the next pandemic is likely to occur approximately within 40 years of the 
last, which will be either before 2008 (counting from the pandemic in 1968) or in 2017, 
depending on whether or not the pandemic in 1977 is accepted [8]. 
 
 
The most severe influenza outbreaks include [9]: 
− 1918-19   “Spanish flu” A (H1N1) 
        >30 million deaths worldwide 
− 1957-58   “Asian flu” A (H2N2) 
        1 million deaths worldwide 
− 1968-69   “Hong-Kong flu” A (H3N2) 
 800,000 deaths worldwide 
− 1977-78   “Russian flu” A (H1N1)      
 
 
       
Figure 2  History of influenza [10] 
 
2.1.1 Influenza versus the common cold 
Signs and symptoms   Influenza   Cold  
 Onset   Sudden   Gradual  
 Fever/chill   Common   Rare  
 Cough   Usual; severe   Less common; mild to moderate  
 Headache   Prominent   Rare  
 Muscle aches and pains   Usual and often severe   Slight  
 Fatigue and weakness   Usual; last up to 2-3 weeks   Very mild  
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2.2 VIRUSES [11] 
Viruses are a major class of microorganisms. They are not dynamic open systems, taking in 
nutrients or expel wastes. A virus particle is a static structure, quite stable and unable to 
change or replace its parts. Only when it infects a cell does a virus acquire the key attribute of 
a living system, reproduction. Unlike cells, viruses have no metabolic abilities of their own. 
And although they contain their own genes, viruses lack ribosomes and therefore depend on 
the cell’s biosynthetic machinery for protein synthesis. Some viruses do also use the host cell 
DNA and RNA polymerases for replication and transcription, respectively. 
 
Many viruses causes disease in the organism they infect, but virus infection does not always 
lead to disease. As an example, avian species can be silent reservoir of influenza A viruses. 
A fully assembled infectious virus is called a virion. The simplest virions consist of two basic 
components: nucleic acid (single- or double-stranded RNA or DNA) and a protein coat (the 
capsid, which functions as a shell to protect the viral genome from nucleases and which 
during infection attaches the virion to specific receptors exposed on the prospective host cell). 
Capsid proteins are coded for by the virus genome. Some virus families also have an 
additional covering called the envelope. Enveloped viruses enter the host cell by fusing either 
with the plasma membrane or with the endosomal membrane following endocytosis. Virus 
envelopes can be considered an additional protective coat. And the fusion of a virus is 
regulated to ensure that the virus particles only fuse with the appropriate host cell membrane 
and not to other virus particles. 
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2.3 INFLUENZA VIRUS 
 
 
 
 
Figure 3 Influenza virus [9]. 
 
 
Classification 
 
The influenza viruses belong to the family Orthomyxoviridae (from the Greek orthos, 
meaning “standard, correct”, and myxa, meaning “mucus”). The orthomyxoviridae family 
contains four genera of viruses: influenza A, B and C viruses, and thogotovirus (sometimes 
called influenza D viruses) [7]. Little is known about the thogotovirus and is therefore not 
discussed any further in this thesis. 
The classification of the influenza viruses are based on their antigenic differences between 
their nucleocapsid and matrix proteins. The genomes of influenza A and B viruses consist of 
eight segments of negative sense RNA whereas influenza C viruses possess only seven 
negative-sense RNA segments. Only types A and B viruses cause clinical disease of any 
concern. The influenza C virus causes less severe respiratory illness which rarely progresses 
to the lower respiratory tract and is most commonly associated with sporadic illness in 
children [12]. 
Influenza A viruses are further classified into subtypes based on antigenic differences of the 
surface proteins hemagglutinin (HA) and neuraminidase (NA), respectively 16 and 9 subtypes 
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have been identified. Influenza type B viruses are not divided into subtypes. The influenza C 
viruses lack the gene which is equivalent to the neuraminidase gene of A and B viruses, and 
has only a single multifunctional glycoprotein, the hemagglutinin-esterase-fusion protein 
(HEF) [7]. 
 
 
 
The different kinds of influenza viruses 
also infect different hosts and have 
different natural habitat. Influenza A 
viruses are found in animals including pigs, 
horses, a variety of avian species and 
humans. In contrast, there is no evidence 
that influenza B viruses infect other hosts 
besides humans and seals. Although 
influenza B virus is mostly associated with 
lower attack rates and a milder disease, it 
may occasionally cause epidemics of the 
same severity as type A viruses[7]. 
 
 
Figure 4 The reservoir of influenza A viruses [7] 
 
 
The currently circulating influenza viruses that cause human disease are of the H1, H2 or H3 
and N1 or N2 subtypes and all of the currently identified 16 HA and 9 NA subtypes of 
influenza A viruses are maintained in wild, aquatic bird populations. Genome segmentation 
facilitating gene reassortment and high mutation rates are the basis for the extraordinary 
genetic variability of influenza viruses. Type B viruses do not exhibit the same degree of 
antigenic variation as does type A [13, 14, 15].  
Viral isolates are described according to type, geographical origin, strain number, year of 
isolation and subtype, in this order (e.g. A/Sydney/5/97 (H3N2)). 
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Virion structure  
 
The Orthomyxoviridae are composed of about 1% RNA, 5-8% carbohydrates, 20% lipid and 
70% protein [7].  They are enveloped viruses that contain a segmented negative single 
stranded RNA (ssRNA) genome. The genome of these viruses encodes at least 10 proteins.  
The viruses are pleomorphic, but usually spherical, filamentous and approximately 80-120 nm 
in diameter. The viral envelope is composed of a lipid bilayer containing transmembrane 
proteins on the outside and matrix protein on the inside. The lipids are derived from the host 
plasma membrane but are selectively enriched in cholesterol and glycosphingolipids. Two 
transmembrane envelope proteins, hemagglutinin and neuraminidase are anchored in the lipid 
bilayer of the viral envelope. Both of these proteins are essential for viral replication. 
Influenza type A has also an third transmembrane protein, M2, an ion channel [16, 17]. These 
proteins are target for antiviral treatment. 
Influenza A viruses most striking feature is the layer with about 500 spikes (NA and HA) 
radiating outward. Usually the viruses have 4-5 times more HA spikes than NA. 
 
2.3.1 Influenza virus replication cycle 
 
The life cycle of influenza virus involves attachment to cell surface receptors, entry into the 
cell and uncoating of the viral RNA followed by replication of the viral genes inside the cell 
nucleus. After the synthesis of new copies of viral proteins and genes, these components 
assemble into progeny virus particles, which then exit the cell by budding from the cell 
surface. The replication site for influenza viruses are the epithelial cells of the upper 
respiratory tract of humans, horses, and pigs.  They replicate extremely well in humans and 
one replication cycle takes only 4-6 h and kills the host [18]. 
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Figure 5   Influenza virus replication cycle [19]. 
 
The HA glycoprotein is responsible for the binding of influenza viruses to their host cells. The 
HA interact with receptor molecules containing sialic acid on the cell surface, initiating virus 
penetration and promotes fusion between the viral envelope and the cell membrane. 
The influenza virus penetrates into the cell by receptor mediated endocytosis. 
After the entry into the cell, the low pH in the endosome induces an irreversible 
conformational change in HA, which ultimately result in membrane fusion between the viral 
and cellular membranes. The acidification of endosomes is brought about by H+-ATPase and 
activates viral M2 ion channels which allow protons to enter the interior of the virus particle. 
The ribonucleoprotein segments (RNP) are released from the endosome when the endosomal 
pH is decreased to ~ 5.0. Viral RNA strands are replicated in the nucleus and new virus 
particles are produced.  
 
The main role of NA is the release of newly manufactured virions from the cell. NA destroys 
receptors recognized by HA by cleavage of the terminal sialic acid residue from carbohydrate 
moieties on surface of host cells. This cleavage facilitates movement of the newly formed 
virus from the surface of infected cells. 
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2.3.2 Neuraminidase (NA) 
 
 
Figure 6 Neuraminidase activity [3] 
 
Neuraminidase (NA) is an integral membrane protein and one of the two subtype specific 
glycoprotein of influenza A and B viruses. NA is an enzyme, a glycohydrolase/sialidase that 
cleaves terminal α-ketosidically linked sialic acids from a large array of glycoproteins, 
glycolipids and oligosaccharides [20]. NA is found on the surface of influenza virus and is a 
homotetramer which accounts for about 5-10 % of influenza virus protein (Figure 3 above). 
NA forms a mushroom-shaped spike with a box shaped head, which is enzymatically active, 
and has a centrally attached stalk containing a hydrophobic region by which NA is embedded 
in the viral membrane. The NA is a prototype class II integral membrane protein, with the N-
terminal in the cytoplasm (as anchor) [21].  
 
 
 By catalyzing the cleavage of sialic acid residues on the surface of infected cells the enzyme: 
⁫ promotes the release of virion 
⁫ prevents the formation of viral aggregates after release from host cells 
⁫ may prevent viral inactivation by respiratory tract mucous and promote the spread of 
virus in the respiratory system 
⁫ may contribute to viral pathogenicity 
⁫ may induce cellular apoptosis and release of pro-inflammatory cytokines [22]. 
 
 
INTRODUCTION 
15 
 
Figure 7 Influenza virus budding [16] 
NA performs a vital function in the final  
stage of the viral life cycle. Without  
functional NA, newly formed viral 
particles remain attached to the host cell 
membrane and form viral aggregates. 
 
 
Nine subtypes of neuraminidase, N1-N9, have been identified for influenza virus type A. No 
subtypes of NA have been isolated for influenza type B. Difference between the type A and 
type B NA amino acid sequence is close to 80%, but the amino acids that bind the 
glycosidically linked sialic acid or its transition state are totally conserved in spatial 
arrangement as well as in chemistry [23]. 
Despite the considerable diversity of the sequences, the residues lining the active site of NA 
are conserved in all wild-type influenza viruses. This makes the active site of NA an excellent 
target for a broad spectrum inhibitor [24]. There are 11 amino acid side chains directly in 
contact with the substrate that never vary in the active site of NA (Figure 14 below) [23]. 
 
Organisms that contain neuraminidase include bacteria (Vibrio cholerae, Clostridium 
perfringens, Streptococcus pneumoniae and Arthrobacter sialophilus) and viruses (especially 
orthomyxoviruses or paramyxoviruses such as influenza virus A and B, parainfluenza virus, 
mumps virus, Newcastle disease virus, fowl plague virus and sendai virus) [25]. 
 
The neuraminidase is also thought to act on the mucin layer in the respiratory tract. Removal 
of the sialic acid lower the viscosity and produce liquefaction, which together with 
mucociliary transport, may help spread the virus through the respiratory tract and permit 
access to the epithelial cells [26]. 
 
The presence of NA on the surface of virions seems contrary to the requirements for viral 
attachment to cells. But different studies of NAs biological role have observed that when a 
virus was culturated in the presence of an neuraminidase inhibitor (NAI), it was restricted to a 
single replication cycle because the progeny became immobilized at the surface of the 
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infected cell (Figure 7) [27]. The NA does therefore not interfere with the entry process of the 
virus. 
2.3.3 Hemagglutinin (HA) 
The name of hemagglutinin has originated from the influenza viruses ability to agglutinate 
erythrocytes by attaching to specific sialic acid containing receptors [7]. The hemagglutinin 
(HA) spike appears to be rod shaped and protrudes from the envelope as a trimer. HA is a 
type I glycoprotein, containing an N-terminal ectodomain and a C-terminal anchor. There has 
been identified 16 subtypes of HA, H1-H16 [28]. And the HA are found on the surface of the 
influenza virus (Figure 3 above). 
 
The HA facilitates entry of the virus by binding to sialic acid containing receptors on the cells 
surface, the initial step in virus replication [21]. HA is also responsible for penetration of the 
virus into the cell cytoplasm. By mediating the fusion of the membrane of the endocytosed 
virus particle with endosomal membrane HA causes release of the viral nucleocapsids into the 
cell cytoplasm [7].  
 
Figure 8 The entry strategy used by influenza virus [11] 
 
 
HA represents the major antigenic determinant of influenza types A and B, and induces 
neutralizing antibodies. For survival, influenza viruses must evade immune recognition by 
process of continual evolution.  
The HA can exist in two different forms, depending on the virus strain, host cell type and 
growth condition. The HA precursor (HA0) is either cleaved protolytically into two disulfide-
linked chains, HA1 and HA2 or remains uncleaved. The HA1 subunit carries the sialic acid 
binding site, and the HA2 subunit is responsible for fusion of viral and cellular membranes. 
Uncleaved HA cannot undergo the low pH induced refolding events associated with HA 
mediated membrane fusion (Figure 8) [7, 29].   
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2.3.4 M2 protein 
The M2 protein of influenza A virus is the prototype viral ion channel protein. It is an small 
integral membrane protein (type III) that is abundantly expressed at the plasma membrane of 
influenza virus infected cells, but only a small amount is incorporated into budding virions 
[30, 31].  
 
 
 
Figure 9 Model for activation of the M2 ion channel [31] 
The model is showing only the transmembran domain  
from residues 24 to 44 (green), His37 (red) and the gate 
Trp41 (blue). And these residues are shown for only two of 
the four subunits. 
 
 
 
 
The M2 protein has a high selectivity for protons (H+ ). Even though the M2 protein is a minor 
component of the viral envelope, the ion channel activity is nonetheless essential in the life 
cycle of the virus. After the influenza virus has entered the cell by endocytosis, the low pH in 
the endosomal compartment activates the M2 ion channel. The acidifying of the interior is 
essential for the uncoating of virions (Figure 8 above). The M2 protein is gated by pH, and 
this property is mediated by the indole moiety of Trp41.When the pH outside the endosome is 
high, the indole moiety of the side chain of Trp41 is blocking the pore of the M2-channel. With 
low pH outside the His37 is charged, allowing rotation of Trp41 to a conformation parallel to 
the pore`s axis, permitting H+ to flow (Figure 9) [31].  
 
The influenza B virus lacks the M2 proteins as found in influenza A viruses. Instead  
influenza B viruses expresses a BM2 protein with is thought to have ion channel activity [7]. 
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2.3.5 Antigenic drift and shift 
Genes of influenza viruses mutate with high frequency, particularly the HA and NA 
glycoproteins against which immunity is directed. Serum antibody to the virus HA is the most 
important factor in immunity. The accumulation of point mutations in the HA and NA genes 
may lead to gradual antigenic change of surface glycoproteins (antigenic drift) and the 
emergence of immunologically distinct strains (antigenic shift). Both of the surface antigens 
of influenza virus undergo extensive variation. Influenza A viruses undergoes frequent 
changes in their surface antigens, whereas type B influenza viruses change less frequently 
[15]. The segmented genome of influenza virus facilitates the exchange of genetic information 
between different influenza viruses (reassortment). This eight different segments can 
theoretically produce 256 different combinations of RNA from the shuffling of the virus [7]. 
 
 
Figure 10   Antigenic drift and shift [32] 
 
2.3.5.1 Antigenic drift 
Drifts are the natural mutation over time of known strains of influenza to evade the immune 
system. Because RNA-directed RNA replication has no quality control mechanism, in 
contrast to DNA replication, RNA viruses are generally more susceptible to the generation of 
mutation leading to serotype formation than the DNA viruses. Errors are produced in 1/104 
bases per replication cycle for RNA-dependent RNA polymerase, whereas DNA polymerase 
produces replication errors only in 1/109 bases per replication cycle [33]. This point mutations 
INTRODUCTION 
19 
leads to amino acid sequence changes in the antibody binding sites (epitopes) on these virus 
proteins. The epitopes of the present virus variant is no longer recognized by human 
antibodies, thereby permitting the virus to multiply and capable of causing illness through 
evasion of the immune response [2]. Antigenic drift occurs in all types of influenza including 
influenza A, B and C. Antigenic drift has also been detected among avian influenza viruses, 
but to a lesser extent than in human viruses. The reason for this is that birds are short lived 
and therefore have limited immunological pressure [2, 21, 34]. 
 
2.3.5.2 Antigenic shift 
Antigenic shifts are far less frequent and are the process by which two different strains of 
influenza viruses combine to form a new subtype having a mixture of the surface antigens of 
the two original strains. This event occurs when two different viruses, possibly each from a 
different host species, co-infect a single host, for instance a pig. The pig then acts like a 
mixing vessel and the genome segments of the two viruses can undergo reassortment. The 
pathogenicity of the new virus are unpredictable, it may lack the requisite virulence factors 
(and therefore get attenuated or frankly non-viable) or it may possess full virulence for 
humans, plus a new surface antigen, usually the HA (from an animal host virus). Such a new 
virus has pandemic potential because it may be intrinsically pathogenic in humans and have 
surface antigens against which the human population lacks any significant immunity. Once a 
pandemic strain is created, it may change its virulence further as it continues to replicate, 
adapting to the host as it does so. Antigenic shift occurs only in influenza A because it infects 
more than just humans. Influenza type B does not exhibit antigenic shifts and therefore do not 
have pandemic potential. This is because influenza B viruses lack an animal reservoir and has 
only one HA and NA subtype [2, 32, 34] 
 
 
2.4 TREATMENT OF INFLUENZA 
The most important protective response against invading pathogens is immunological and 
immunity after an influenza infection may last for many years. For many other viruses, a 
single infection of a young child confers a lifelong immunity. 
 
The immune system produces both interferons and antibodies under the infection of influenza 
virus. The interferons are produced shortly after the viral titer has reached its peak, while 
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antibodies (IgG is most important), are not detected until later in the recovery and are 
responsible for the final clearing of the virus [26]. 
Inactivated influenza virus vaccines have been used in prevention of influenza viruses for 
about 50 years. Although vaccination has been successful in eliminating a few viruses from 
the world (e.g. smallpox and polio), many viruses have developed ways to escape from the 
immune system. The antigenic variation of influenza viruses was detected in the 1940s. The 
influenza virus has a limit to how much variation it can tolerate. Mutation to escape 
neutralizing antibodies of the immune system must also preserve the function of the surface 
proteins. An ideal influenza vaccine would be directed against these essential regions, where 
mutation would result in loss of viability. Crystal studies of the surface glycoproteins shows 
that these regions usually are in depression on the viral surface and are generally inaccessible 
to antibodies. They are however accessible to small molecules and this is the reason for why 
so much effort is being directed toward the development of antiviral drugs that bind to these 
conserved sites and inhibit the viral function [23].  
 
Until a few years ago, there were only two options available to reduce the impact of the 
influenza virus, vaccines and the antiviral M2 inhibitors, amantadine and rimantadine. 
Although protection through vaccination is limited due to the frequent antigenic shift, 
vaccination has for a long time been, and still are, the first line defence against influenza virus 
[35]. The use of M2 inhibitors is now limited, because of rapid emergence of resistant viral 
strains which reduces their effectiveness, its relatively high frequency of adverse effect and 
lack of activity against influenza B virus. In 1999 the first neuraminidase inhibitor was 
approved for treatment of influenza. Zanamivir (Relenza®), developed by GlaxoSmithKline, 
was the first drug in this new class of inhibitors and designed after crystal studies of the 
neuraminidase enzymes active binding site. Three years later Roche licensed the second 
neuraminidase inhibitor, oseltamivir (Tamiflu®). Unlike zanamivir, oseltamivir was approved 
for both prophylaxis and treatment of influenza virus. This class of inhibitors has a major 
advantage, they target a highly conserved region in the neuraminidase enzyme and resistance 
is therefore less likely to occur. Oseltamivir is now the first choice of the antiviral drug 
against influenza virus and is effective against all strains of influenza virus, also the 
threatening and potential pandemic H5N1 strain.  
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2.5 ANTIVIRAL AGENTS AGAINST INFLUENZA VIRUS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11 Potential antiviral targets in the influenza virus (modified from Leonard et al. [36]) 
 
The basic biology and reproductive mechanism varies widely between different viruses and 
unique strategies are needed to inhibit each particular virus. In the figure above, some of the 
potential viral targets in the influenza virus are displayed. Currently only antiviral drugs 
which inhibit the uncoating/endosomal escape and the budding process are approved for 
medical use (Table 1). Small interfering RNAs (siRNAs) which interfere the replication of 
mRNA and inhibitors of influenza virus polymerase are studied as potential antiviral agents, 
but much work remains to be done before clinical success is realized [36, 37]. The structure of  
the compounds under clinical and preclinical evaluation can be found in Figure 15 below.  
 
Table 1 The past, present and future of antiviral compounds against influenza virus1 
Compound 
VIRUS Viral target Comments 
Approved for 
medical use 
In clinical 
development 
In preclinical 
evaluation 
 Orthomyxo 
Matrix (M2) 
protein 
Target for 
inhibition 
Amantadine 
 
    
  
   Rimantadine     
  Neuraminidase 
Target for 
inhibition Zanamivir Peramivir [39] A-192558 
     Oseltamivir   A-315675 
                                                 
1
 Modified from reference  38. E. E. De Clearcq, A guided tour through the antiviral drug field, Future 
Virology 1 (2006), no. 1, 19-35. 
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There are two classes of antiviral agents against influenza viruses, the M2 inhibitors and the 
neuraminidase inhibitors. These two classes of antivirals are effective against different types 
of influenza viruses.  
 
Even though hemagglutinin plays a major role in the influenza viruses entry process of the 
cell, blocking of hemagglutinins sialic binding site may not be the best strategy for designing 
antiviral agents against influenza viruses. This is because studies have indicated that influenza 
viruses can enter cells without the assistance of sialic acid and also in the absence of a 
functional sialic acid binding site on hemagglutinin [23]. 
2.5.1 M2 inhibitors, the amantadanes 
 
NH2
NH2
RimantadineAmantadine
 
 
The amantadanes were identified by traditional biologic screening assays in the early 1960s 
[40]. Amantadine and its analogue rimantadine were the first antiinfluenza drugs and block 
the ion channel of virus protein M2 (Figure 9 above). These drugs block the acidification of 
the virions interior and the release of transcriptionally active ribonucleoprotein complex for 
the transport to the nucleus. A second additional effect of amantadine and rimantadine is the 
blockade of HA maturation during the transport from the endoplasmic reticulum to the plasma 
membrane [7]. 
 
The M2 inhibitors are only active against type A influenza viruses, because the influenza B 
virusese lack the M2 protein [41]. Amantadine and rimantadine were approved for the 
prevention and treatment of influenza A in 1976 and 1993, respectively [42]. However, these 
drugs are not available on the Norwegian marked and they have never achieved widespread 
acceptance because of the rapid development of viral resistance, their lack of activity against 
influenza B and, in the case of amantadine, adverse events (e.g. anxiety, lightheadedness, 
seizures) [7]. These adverse events are also more evident in elderly patients. 
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Rimantadine exhibit fewer side effects in the central nervous system than amantadine at 
comparable doses, the reason for this might be because amantadine is excreted intact in the 
urine, while >90 % of the rimantadine dose is metabolized through hydroxylation at multiple 
sites [43]. 
 
Complete cross-resistance against amantadine and rimantadine is associated with a single 
nucleotide change in the M2 protein after a single passage in vitro and from a single host in 
vivo [23]. The resistant variants are also transmissible and fully pathogenic.   
  
Amantadine has also an anti-parkinson effect which was serendipitously discovered during a 
course of prophylaxis for influenza [40]. And amantadine are now recommended for use in 
elderly patients with drug induced parkinsonism [44].  
 
 
2.5.2 Neuraminidase inhibitors (NAI) 
 
 
Figure 12 Neuraminidase inhibitors [3] 
 
 
The neuraminidase inhibitors (NAI) interfere with the release of progeny influenza virus from 
infected host cells. Thereby it prevents infection of new host cells and halts the spread of the 
infection in the respiratory tract. NAIs are effective against both influenza type A and B, and 
the inhibition is reversible [45]. 
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Figure 13 Mechanism of neuraminidase hydrolysis [46] 
 
Two neuraminidase inhibitors are currently licensed as drugs for the treatment of influenza 
virus, they were both invented after determination of the crystal structure of the influenza 
virus NA in 1983. They are developed by structure-based drug design, to target conserved 
residues at the neuraminidase enzyme active site in influenza A and B viruses [23].  
The structure clarification also led to the recognition of the oxocarbonium ion as the likely 
intermediate in NA hydrolysis, and hence analogs were synthesized as likely candidates for 
inhibitors (Figure 13) [23]. The first inhibitor to be synthesized was DANA (2-deoxy-2,3-
dihydro-N-acetylneuraminic acid, Neu5Ac2en), which were effective in vitro but did not 
inhibit replication of influenza viruses in animals.  After the structure clarification of NA, 
DANA served as the lead compound in the rational design of drugs targeting the NA. 
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Figure 14  Sialic acid in the active site of neuraminidase [35] 
Atoms are colored as following: red for oxygen, blue for nitrogen, green for NA 
carbon and orange for sialic acid carbon. Dashes indicate H-bonding (red) and any 
hydrophobic (black) interactions, only side chains are shown and some active 
residues are omitted for clarity.  
 
2.5.2.1 Zanamivir (Relenza®, GlaxoSmithKline) 
Zanamivir (Figure 13 above) is a sialic acid analog which was first described in 1993 by  
von Itzstein et al. [20]. Zanamivir was designed after study of DANAs binding to 
neuraminidase (DANA is the unsaturated sialic acid analogue). Zanamivir (Relenza®) was the 
first inhibitor to be synthesized which specific inhibited the neuraminidase and was approved 
for influenza treatment in 1999. Zanamivir is modified at C4, where hydroxyl group of sialic 
acid is substituted with a guanidine group [47]. This replacement filled an unoccupied pocket 
in the NA active site and increased the binding interactions, which was confirmed by x-ray 
crystallography [7]. 
 
Zanamivir is a highly polare molecule, which does not penetrate cell membranes readily. This 
confers a low bioavailability and zanamivir must therefore be administered by inhalation. 
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Zanamivir is contraindicated in patients with underlying respiratory disease because of the 
risk of serious adverse events like bronkospasm and allergic-like reactions might occur. 
2.5.2.2 Oseltamivir (Tamiflu®, Roche) 
 
Oseltamivir is the ethyl ester prodrug of the neuraminidase inhibitor oseltamivir carboxylate. 
Oseltamivir carboxylate has a cyclohexene ring instead of a sugar ring and modifications at 
both C4 (hydroxyl group → amino group) and C6 (glycerol side chain → pentyl ether group), 
compared to the oxocarbonium ion intermediate [47]. When given as an early treatment of 
influenza oseltamivir shorten the duration of illness by 1.5 days. 
 
View point 2.7 TAMIFLU® (ROCHE) below. 
 
2.5.3 Other neuraminidase inhibitors 
 
Screening procedures have identified other molecules that inhibit influenza NA. Plant 
flavonoides have for example been investigated for years, but they are not very potent  
(Ki 10-5 M) and their mechanism of action is still unclear [23]. 
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Figure 15 Potential neuraminidase inhibitors 
 
Figure 15 shows three promising potential neuraminidase inhibitors in different phases in the 
research and development pipeline. A-192558 and A-315675 are under preclinical evaluation 
while peramivir has undergone phase III clinical trials. Peramivir has been reported with high 
NA inhibitory activity and was designed from studies of DANA and its interactions with 
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influenza neuraminidase. It is a very promising drug and the in vitro potency appears to be 
greater than either zanamivir or oseltamivir carboxylate, based on the generally lower EC50 
values [48]. 
2.5.4 Other antiviral agents against influenza viruses 
2.5.4.1 Protease inhibitors 
Influenza virus encodes a multifunctional enzyme, RNA polymerase, which catalyzes both 
transcription and replication of the RNA genome. Although the enzyme is known to be 
important for the replication, the exact function of the enzyme is poorly understood [49]. 
Most of the marketed antivirals are nucleoside analogue that have been modified to inhibit 
only polymerases in virus effected cell, but there is still not marketed any specific inhibitor of 
influenza polymerase. Influenza viruses also uses a protease to cleave the mature form of 
hemagglutinin (HA0) to HA1 and HA2 [28]. But this cleavage is mediated by cellular 
proteases, so for influenza, this step is no viral target for inhibition [23]. Nucleoside 
analogues have also an major drawback, they are usually toxic compounds. 
 
Ribavirin 
Ribavirin is a synthetic nucleoside and is currently licensed in Norway as Copegus® (Roche) 
and Rebetol® (Schering-Plough). Both of theses drugs are approved for use against chronic 
hepatitis C, but not as monotherapy. In addition Copegus® can be used in combination 
therapy in patients coinfected with clinical stabile human immunodeficiency virus (HIV). 
Ribavirin is not approved for treatment of influenza in Norway, but is used in some countries. 
 
 
In vitro studies of ribavirin aerosol has shown inhibitory 
effect on the influenza A and B viruses and are therefore 
under preclinical evaluation [50]. Ribavirin is a broad 
spectrum, virustatic chemotherapeutic agent. It is effective 
against a very wide range of viruses, both RNA and DNA, 
but the precise mechanism of action is still unknown.  
 
 
 
 
Ribavirin
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2.5.4.2 Recombinant interferon α 
Interferon (IFN) α is a familiy of approximately 20 proteins with similar activities. IFNα plays 
a normal part of the immunological response to presence of viruses [51]. IFNα has been 
shown to induce B-lymphocytes to differentiate into antibody producing plasma cells and is 
necessary for the production of IgG in the response of influenza infection. IFN α is a powerful 
adjunct when mixed with influenza vaccine [52]. 
 
2.6 RESISTANCE 
2.6.1 Resistance to neuraminidase inhibitors 
Resistance to neuraminidase inhibitors (NAI) is a major concern in the treatment of a 
pandemic influenza and WHO established in 1999 the global Neuraminidase Inhibitor 
Susceptibility Network (NISN). Currently, NISN has not found any influenza isolates with 
spontaneous resistance. 
 
Resistance to NAI might arise in two ways [53, 54]: 
1. Mutation of the viral neuraminidase in order to prevent the drug binding to its target. 
However, NAIs bind to the highly conserved active site of the neuraminidase, this is 
expected to make the resistance selection difficult and unlikely to develop because 
they would result in an unfit virus 
2. Mutation of the viral hemagglutinin in order to reduce its binding affinity to sialyl 
residues. This would facilitate viral release without the necessity for neuraminidase 
activity and, hence, produce virus resistant to NAIs (as a class). The fact that the 
hemagglutinin mutants have so far been found to be as susceptible to the NAIs as the 
wild-type viruses in animal experiments, suggests that the neuraminidase may play 
some vital role other than receptor destruction in the infection process. Possibly the 
enzyme is required to facilitate the movement of virus particles through respiratory 
secretions, and thus if it is blocked, the virus may be trapped and immobilized. 
 
In summary, although the development of resistance to the neuraminidase inhibitors in the 
clinical settings requires further study, available data suggest that resistance to this class of 
compounds is unlikely to limit their clinical usefulness. This is also supported by the fact that 
mutant viruses resistant to either zanamivir or oseltamivir carboxylate have been difficult to 
generate in vitro and it is therefore suggested that they might not develop easily in vivo [53]. 
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However, resistance to neuraminidase inhibitors have been observed in both treated children 
and adults. But no transmission of oseltamivir-resistant virus between humans have so far 
been documented [3]. 
 
 
2.7 TAMIFLU® (ROCHE) 
 
2.7.1 Description 
Tamiflu® (oseltamivir phosphate) is available as a  
capsule containing 75 mg oseltamivir for oral use,  
and as a powder for oral suspention (12 mg/ml), 
produced by Roche. 
Tamiflu is indicated for the prophylaxis and treatment  
of influenza in patients 1 year and older [55]. 
Drug administration guidelines for adults are  
75 mg in twice daily doses. 
       Figure 16 Tamiflu capsules and mixture 
 
2.7.2 Discovery of oseltamivir carboxylate  
Oseltamivir carboxylate (GS 4071) was first described by Kim et al. in 1997 [56]. 
Oseltamivir carboxylate is a carbocyclic transition state analogue inhibitor of influenza 
neuraminidase (NA) that was synthesized by researches at Gilead Sciences in California, 
based on the known structure of the active site of NA. 
Oseltamivir was approved for propylaxis and treatment of influenza in Norway in 2002. 
 
Oseltamivir carboxylate is a more potent inhibitor of neuraminidase than zanamivir (Ki 0.3-
0.8 versus 1.1-3.5 nM respectively) [57].  
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Figure 17 Oseltamivir and oseltamivir carboxylate are designed from DANA 
 
After detailed analysis of the X-ray crystal structure of neuraminidase and the 
oxocarboniumion intermediate of sialic acid, indications of several critical interactions was 
detected. Two of these interactions help to anchor the schaffold of sialic acid in the active site 
of neuraminidase and these interactions are preserved in both oseltamivir and zanamivir: 
 
1) Negative charged carboxylate group which interacts with the positively charged side 
chains of the three Arg (Arg118, Arg292 and particular Arg 371) 
 
2) N-acetyl group makes both nonpolar and polar contacts with Arg152, Trp178 and 
Ile222 
 
Figure 18 below shows the interactions between neuraminidase and oseltamivir carboxylate. 
This figure displays that the NA active site can be divided into three major binding pockets. 
Pocket 1 is formed by highly polar residues (Glu276, Glu 277, Arg292 and Asn 294) in 
addition to the hydrophobic Ala 246. Different studies has discovered that although this 
pocket appears to be highly polar in nature, it has been the key in achieving high binding 
affinity with cyclohexene based neuraminidase inhibitors [56]. The Glu276 side chain can 
also adopt two different conformations, one of them makes pocket 1 larger and creates a much 
less polar environment. Pocket 2 is a hydrophobic pocket which is not utilized by sialic acid 
for binding (Figure 14 above). The third binding pocket is large and contains both 
hydrophobic and hydrophilic residues. 
INTRODUCTION 
31 
 
Figure 18 Oseltamivir carboxylate (GS 4071) and neuraminidase X-ray crystal structure [35] 
Atoms are colored as following: red for oxygen, blue for nitrogen, green for NA carbon and 
orange for GS 4071 carbon. Dashes indicate H-bonding (red) and any hydrophobic (black) 
interactions, only side chains are shown and some active residues are omitted for clarity. 
Glu276 is also rotated away from the center of pocket 1. 
 
The design of oseltamivir carboxylate is based on that there are no direct interaction between 
the sugar ring DANA and NA, implying that the position of atoms in the ring is not critical 
[23]. The C-7 hydroxyl of the glycerol side chain (Figure 14 above) did not interact with 
amino acid residues in the NA active site and therefore an oxygen atom was incorporated as a 
replacement for the C-7 hydroxy methylene unit. A lipophilic alkyl group was added to this 
oxygen atom to balance for the effects of the polar functional groups present in the molecule, 
to enhance the overall oral bioavailability [35]. The length, substitution and geometry of this 
C-3 was determined through several studies of neuraminidase inhibitory activity. These 
studies indicated that the 3-pentyl group adjacent to the ether oxygen led to a significant 
increase in potency. This 3-pentyl side chain revealed hydrophobic interaction previously not 
observed in the sialic acid/neuraminidase complex, resulting in significant increased binding 
affinity. 
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The position of the double bound on the neuraminidase inhibitor oseltamivir carboxylate was 
chosen after several structure activity relationship studies by Kim et al. [56]. 
 
In general, the common characters of importance for binding to NA can be described as 
followed (numbering from Figure 18 above):  
1) A cyclic schaffold connected to three or four substituents – binds in pocket 1 
2) A carboxylic group at C-1 position, necessary for strong electrostatic interactions with 
a triad of arginine residues 
3) Two hydrophobic groups at C-3 and C-4 position – binds in pocket 2 
 
Oseltamivir carboxylate is a transition state inhibitor of viral neuraminidase and has 
demonstrated potent in vitro and in vivo antiviral activity against influenza virus. However, 
the oral bioavailability of oseltamivir carboxylate was less than 5 % in rats, and a ethyl ester 
prodrug was designed, which is more hydrophobic and increased the bioavailability to 75 % 
[58]. 
 
 
2.7.3 Pharmacodynamics 
 
2.7.3.1 In vitro antiviral activity 
In enzyme assays, oseltamivir carboxylate inhibits NA of influenza A viruses with a Ki of  
0.1-1.3 nM and influenza B viruses NA with Ki of 2.6 nM [55]. 
Concentrations of oseltamivir carboxylate required to inhibit NAs of other viruses and 
bacteria with NA are at least 105 times greater than that inhibit influenza NA [57]. 
 
2.7.3.2 Safety and toxicity in animals 
Oseltamivir is well tolerated in mice, ferrets and rats. Mice tolerated doses up to 100 
mg/kg/day and rats as much as 800 mg/kg/day. These doses, on weight basis, are 50 and 400 
times, respectively, grater than the recommended therapeutic dose for adult patients [57]. 
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2.7.4 Pharmacokinetics 
2.7.4.1 Absorption, bioavailability, distribution, metabolism and elimination [55] 
Oseltamivir is readily absorbed from the gastrointestinal tract after oral administration  
of oseltamivir phosphate and is extensively converted predominantly by hepatic esterases to 
oseltamivir carboxylate. At least 75 % of an oral dose reaches the systemic circulation as 
oseltamivir carboxylate. 
 
The volume of distribution (Vd) of oseltamivir carboxylate by steady state is approximately  
23 liters for humans, a volume which are equivalent to the extracellular body fluid. 
The binding of oseltamivir carboxylate to human protein is low, only 3 %. The binding of 
oseltamivir to human plasma protein is 42 %, which is insufficient to cause significant 
displacement-based drug interactions [42]. Protein binding also slows the elimination of drugs 
that are removed from the serum by renal clearance. Oseltamivir carboxylate has a low 
protein binding and are therefore quickly removed from the circulation. Oseltamivir 
carboxylate must therefore be taken twice daily and possibly in larger doses than if the protein 
binding had been higher.  
 
In vitro studies have shown that neither oseltamivir nor oseltamivir carboxylate is a substrate 
for, or inhibitor of, cytochrome P450 isoforms. 
 
Absorbed oseltamivir is primarily (>90%) eliminated by conversation to oseltamivir 
carboxylate. Oseltamivir carboxylate is not further metabolized and is eliminated in the urine. 
Oseltamivir carboxylate is eliminated entirely (>99%). Renal clearance (18.8 l/h) exceeds 
glomerular filtration rate (7.5 l/h) indicating that tubular secretion occurs, in addition to 
glomerular filtration. Less than 20 % of an oral radiolabeled dose is eliminated in feces. The 
elimination is of first order kinetic and the half life of oseltamivir carboxylate is 6-10 hours. 
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2.8 AVIAN FLU 
Aquatic birds provide the natural reservoir for influenza A viruses and are the source of all 
influenza viruses in other species, but in general, avian influenza is asymptomatic in wild 
birds. Only occasionally, highly pathogenic strains of influenza cause serious systemic 
infections in domestic poultry. 
All avian influenza viruses are classified as type A, and are the key contributors to the 
emergence of human influenza pandemics. Different studies have defined two types of avian 
influenza A viruses based on their virulence: a highly virulent type that causes fowl plagues, 
and an avirulent type that causes only mild disease or asymptomatic infection. The history of 
highly virulent avian influenza viruses have clearly demonstrated that all of the pathogenic 
avian influenza A viruses are of the H5 or H7 subtype. There appears to be no association of 
NA subtypes with virulent viruses [21].  
 
 
Figure 19  The avian, human and swine upper respiratory tract epitheliae preferentially  
    express α 2-3 linkage, α 2-6 linkages and both linkages, respectively [59].  
 
The avian influenza virus that appears most threatening now is the H5N1 strain, which 
recently is a growing concern in Asia. Before 1997, no evidence had indicated that the H5N1 
viruses could infect humans and cause fatal disease. Now it has infected also cats, pigs and 
other mammals, often with fatal results. A human pandemic with H5N1 virus could 
potentially be catastrophic because most human populations have negligible antibody 
mediated immunity to the H5 surface protein and this viral subtype is highly virulent. 
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Influenza in avians is an infection of the gastrointestinal tract, with transmission 
predominantly through faeces. This fecally contaminated water-oral route is a major 
mechanism of virus transmission amoung aquatic birds and from migratory birds to domestic 
poultry over a wide area. The migratory birds are also important for the transmission of avian 
influenza between the Northern and Southern Hemisphere [21]. 
Influenza A viruses are carried asymptomatically in the gastrointestinal tract of wild birds, but 
may cause disease in domestic birds and in mammals such as humans and pigs. Similarly, 
human viruses do not replicate efficiently in waterfowl when introduced by natural routes. 
The tracheal epithelia of birds and humans mainly express influenza A receptors with an α 2-3 
linkage and α 2-6 linkage of sialic acid, respectively, whereas pig tracheal respiratory 
epithelium expresses receptors with both α 2-3 and α 2-6 linkages [60]. 
The specificity of HA for sialic acid in α 2-3 or α 2-6 linkage to galactose is a key determinant 
in restricting the transfer of influenza virus directly from avian species to humans without 
mutations in HA sialic acid binding site occurring.  
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Figure 20  Sialic acid residues covalently attached to galactose residues via  
   either α 2-3 or α 2-6 linkages 
 
As of October 2006 the outbreak has resultet in 151 human deaths according to the World 
Health Organization, most of them in Asia and with history of exposure to sick and dead 
poultry in their neighbourhood [61]. Recent epidemiological evidence indicates that human-
to-human transmission of avian H5N1 can occur. This is a growing concern because it 
suggests that only minor alternations in current avian H5N1 strains might result in efficient 
human-to-human transmission, a necessary condition for a human pandemic [59].  The 
pathogenicity of the virus has also made it difficult to produce an effective vaccine. The 
H5N1 influenza strain is so pathogenic that it could not be grown in embryonated eggs  
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because it killed the embryos before high levels of virus were produced [7]. In addition their 
virulence is a threat to the personnel in the vaccine production. The H5N1 strains are however 
sensitive to NA inhibitors and both national and international stockpiles of neuraminidase 
inhibitors are established for rapid response at the start of a pandemic. 
 
 
2.9 COUMARIN 
 
In this thesis coumarin was chosen as the pro moiety for the new potential prodrugs of 
oseltamivir carboxylate. The major advantage by using coumarin as pro moiety is that 
coumarin has been studied for more than 200 years [62]. The toxicity profile of coumarin is 
therefore well known and it is found to be relatively nontoxic in many clinical and laboratory 
studies [63, 64]. 
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Figure 21 Coumarin 
 
Coumarin is a naturally occurring secondary metabolite, being present in a widely variety of 
plants, microorganisms and in some animal species. Coumarin was first isolated from the 
seeds of the Tonka tree (Dipteryx odorata) [62]. The natural sources has never played a role 
in the isolation of coumarin, because the synthesis is simple and inexpensive [65].  Coumarin 
is used widely as a fixative and enhancing agent in perfumes and is added to toilet soap and 
detergents, toothpaste, tobacco products and some alcoholic beverages. Large quantities are 
also used in rubber and plastic materials and in paints and sprays to neutralize unpleasant 
odours. 
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Figure 22 Picture of the Tonka tree and dried tonka beans 
 
The metabolism of coumarin displays large interspecies differences, with the rat 
demonstrating enhanced susceptibility to hepatic injury due to the 3,4-epoxidation pathway. 
The major metabolic pathway in humans is to 7-hydroxycoumarin via cytochrome P450 2A6. 
The 7-hydroxycoumarin is excreted in conjugated form, almost completely as glucuronide in 
the urine [65]. Since very few drugs are substrate for the CYP 2A6 isoenzyme, drug 
interactions involving this enzyme are therefore not likely to occur. 
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Figure 23 Illustration of the coumarin prodrug concept 
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2.10 PRODRUG 
 
Definition: 
“Prodrugs are chemicals with no pharmacological activity requiring biotransformation 
within the body in order to release the therapeutically active metabolite [66].” 
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Figure 24 Schematic illustration of the prodrug concept [67] 
 
The prodrug concept was introduced in 1958 by Adrien Albert [68]. And as defined, prodrugs 
are therapeutic agents that are inactive per se but are predictably transformed into active 
metabolites. The prodrug strategy is important for improvement of the physiochemical and 
biological properties of an parent molecule. A necessary requirement of this approach is the 
capability of the drug to revert to the parent drug in the body by enzymatic or chemical action, 
quantitatively and at a desirable rate. 
 
There are many barriers a drug has to overcome, before it can be released at the desired time 
and site in a biological system [69]. Some of them are mention below: 
 
Pharmaceutical Pharmacokinetic  Pharmacodynamic 
- irritation or pain - incomplete absorption  - toxicity     
- chemical instability    (high/low lipophilicity) - adverse effects 
- low/high lipophilicity - short duration of action  
- offensive taste or odor - low or variable bioavailability  
- poor aqueous solubility - marked presystemic metabolism  
 - unfavorable distribution in the body 
    (lack of site specificity) 
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Prodrugs can be obtained by direct attachment of a functional group to the pro moiety 
molecule.  In the rational design of prodrugs, three basic steps have to be considered. That is 
the identification of the parent drug delivery problem, the physiochemical properties required 
for maximum efficacy or delivery and the choice of prodrug moiety.  The chosen pro moiety 
should provide a prodrug which exhibit the proper physiochemical characteristics and which 
can be cleaved in the desirable biological compartment [66]. The conversation of prodrug to 
parent drug is mediated either by enzymes (esterases and lipases) or by pH. 
 
The most common type of prodrugs are esters derivative from hydroxyl or carboxyl groups 
present in the parent drug molecules, but there are many other bioreversible derivatives for 
many other functional groups. The reason for the popularity of ester as prodrug is the fact that 
the organism is rich in enzymes capable of hydrolyzing ester bonds, they are ubiquitous 
distributed and several types are found in the blood, liver, and other organs and tissues. By 
appropriate esterification it is possible to obtain derivatives with almost any desirable aqueous 
solubility or lipophilicity [66]. While there has been an abundance of work done on ester 
prodrug, much less work has been completed on prodrugs of amids [70]. This is due to the 
relatively high stability of amids in vivo, which makes the regeneration of the original drug 
more difficult. The prodrug approach has also been successfully applied on a variety of other 
drugs to design derivatives, but these are not further mention here. 
 
Application of the prodrug approach: 
- improved formulation (e.g. modify aqueous solubility, mask bitter taste) 
- improved chemical stability 
- improved patient acceptance and compliance 
- improved bioavailability 
- improved organ selectivity 
- site specific bioactivation 
- decreased side effects 
- marketing considerations  
- prolonged duration of action (slow release of the parent drug from a prodrug,  
 decreased first-pass metabolism of the drug) 
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2.10.1 Pharmacokinetic aspects of prodrug design 
 
The pharmacokinetic of a prodrug is dependent on several factors, some of them are 
percentage of protein binding, rate of the esterase breakdown and clearance from the body. 
 
 
 
Figure 25 Pharmacokinetic of a 
protein bond prodrug 
The amount of free prodrug 
available for hydrolytical esterase 
breakdown is in equilibrium with 
the amount of prodrug bound to 
albumin. K1 is the rate of esterase 
breakdown, while k2 is the 
clearance rate of the active drug. 
  
 
 
 
 
Following is a hypothetically example of the pharmacokinetic of a prodrug: 
A drug has a therapeutically window between 2-10 µg/ml (plasma concentration), 
the maximum bolus dose gives a plasma concentration of 10 µg/ml. The prodrug is 
nontoxic and can be administrated in amounts giving a plasma concentration of up to 
0.6 mmol/l. At this concentration half of the binding capacity of albumin is saturated 
and displacement of other compounds is not likely to occur [51]. The kinetics is of 
1st order, with the value k1, and the belonging k2 is 0.5 hours-1. As indicated in 
Figure 25 k1 is dependent on the protein binding and the rate of esterase breakdown. 
The drugs volume of distribution of highly protein bound drugs is low. 
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   a)          b)  
 
Figure 26 Hypothetically time courses following intravenous administration of drug and prodrug 
Blue = drug followed an i.v. dose of drug, green = drug followed an i.v. dose of prodrug and  
red = lowest part of the therapeutic window 
 
The Figure 26a) above the value of k1= 0.5. It display the injection of twice the molar amount 
of prodrug compared to injected parent drug, the concentration of drug from prodrug never 
rises above the upper part of the therapeutic window. The concentration of drug from prodrug 
also lies twice as long inside time therapeutic window as the parent drug. In case of Figure 
26b) the value of k1=0.1. Six times the molar amount of prodrug is injected compares to the 
parent drug. The concentration of drug from prodrug stays also here inside the therapeutic 
window and has approximately 5 times longer duration of effect without exceeding the upper 
part of the therapeutic window. 
In summary, the hypothetically example in Figure 26 shows that a prodrug can have major 
advantage compared to the parent drug. It can be administrated in a larger dose which gives a 
longer duration of effect without exceeding the therapeutic window. The patients compliance 
will therefore increase, as the frequency of dose administration decreases. The prodrug might 
be administrated only once dose a day, once a week or one dose might be sufficient for the 
hole treatment, which often is the case for Azitromax® which, due to active metabolites and 
the drug itself, stays in the body for several days.  
 
Oseltamivir is the ethyl ester of its active metabolite and is hydrolyzed due to extensive first 
pass metabolism, which is relatively normal for simple ester prodrug. Certain drug, for 
example pivampicillin, is design as prodrugs to increase the oral bioavailability and the fast 
hydrolysis to its active metabolite is advantageous. This is similar to oseltamivir, the ethyl 
ester was designed to increase the oral bioavailability, not its duration of effect. In this thesis, 
amid prodrug is designed to increase the binding to human serum protein. These prodrugs are 
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among the few which have a free carboxylic group and the strategy is to investigate if these 
prodrugs can avoid the first pass metabolism and remain in the circulation for a longer time 
then oseltamivir. To confirm that this might be the case for these new prodrugs, many further 
studies have to be preformed. 
  
2.10.2 Pro- prodrugs 
 
 
Pro-Prodrug Prodrug DrugBiological Chemical
 
 
Figure 27 Schematic illustration of the pro-prodrug concept 
 
 
A pro-prodrug is a derivative which must undergo two independent reactions in order to 
regenerate the parent drug. The prodrug intermediate possesses a high chemical reactivity, 
allowing it to rapidly convert to the parent drug. This chemical reaction cannot occur before 
the biological conversation of the pro-prodrug (a chemically stable molecule) to its prodrug 
form. Since simple amids are generally are too stable in vivo to be useful prodrugs forms for 
amines, many investigators have attempted to prepare amides which utilize an intramolecular 
reaction (e.g. lactonization) to increase the lability of the amide bond, thus facilitating release 
of the amine [66, 71]. A strategy to overcome this problem is the pro-prodrug concept. 
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Figure 28    The concept of a coumarin based esterase sensitive prodrug system 
This prodrug concept takes advantage of intramolecular cyclization reactions. 
 
The design of this prodrug system takes advantage of the facile lactonization of cinnamic acid 
and its derivatives. But the major advantage of this system is that the toxicity profile of 
coumarin is well-known and coumarin has been found to be relatively non-toxic in many 
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clinical and laboratory studies [63]. It is a pro-prodrug concept were the pro-prodrug form is 
susceptible to esterase metabolism, and the prodrug can there by undergo spontaneous 
cyclization, regenerating the drug and the coumarin pro moiety.  
 
2.11 PROTEIN BINDING 
 
Many drugs bind to proteins in plasma. Albumin is the most important drug binding protein 
although α1-acid glycoprotein, β-globulin, α1-globulins, α2-globulins and lipoproteins also 
binds and carry a wide variety of drugs.  
The drug binding to plasma and tissue proteins are fundamental factors in determining the 
overall pharmacological activity of a drug. And the drug binding depends on three factors; the 
concentration of free drug, its affinity for the binding sites and the concentration of protein. It 
is the unbound drug that is pharmacologically active and can undergo metabolization. 
Therefore the extent of binding of a drug to plasma protein controls both its effect and the 
duration of the effect. Competition between drugs that binds to the same site in albumin is a 
frequent cause of drug interaction and can cause serious toxicity owning to the increased 
concentration of the drugs free form. This is the case for drugs that has relatively narrow 
range of therapeutic concentration and are more than 90% bound to albumin [72]. And there 
are few drugs that affect binding of other drugs because most of them occupy, at therapeutic 
concentration, only a tiny fraction of available binging sites. 
 
 
2.11.1 Albumin 
 
The name albumin origins from the Latin word albus, which means white. More general it 
evolved from the term albumen, which is an early German word for protein. The albumen is 
still used in for the white of an egg, for the secretion of the snail and for urinary proteins as a 
group. The albumin is specifically used for protein from blood plasma or to a protein with  
similar properties [72].  
 
 
Human serum albumin (HSA) has a molecule mass of approximately 66.5 kDa and is the 
most abundant protein in blood plasma. Albumin accounts for approximately 60% of all 
plasma proteins and the usually concentration is about 0.6 mmol/l in the bloodstream.  
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Albumins ability to bind smaller molecules 
of many types is well known, and the most 
studied ligand which binds to albumin is 
bilirubin. The albumin molecule has two 
primary binding sites, Sudlows site I and II, 
but several other binding sites for drugs has 
also been identified on the protein. These 
other binding sites have a lower binding 
affinity and selectivity.  
 
 
 
 
 
Figure 29 Three domain structure of HSA [73] 
 
 
Sudlows site I  binds mainly hydrophobic, bulky, heterocyclic molecules with a centrally  
 located negative charge (e.g. warfarin, phenylbutazone).  
 
Sudlows site II  binds mainly aromatic carboxylic acids with a negative charge at one end of  
 the molecule distal from the remaining hydrophobic structure (e.g. diazepam,  
 ibuprofen).  
 
One of albumins main functions is transporting endogenous and exogenous (e.g. drugs) 
compounds and it act like a buffer on the free drugs concentration [73]. The protein binding of 
endogenous compounds (such as hormones) exhibits higher affinity and specificity than those 
of exogenous compounds. Binding of drugs to albumin alters the pattern and volume of 
distribution, can lower the rate of clearance and increases the plasma half life of the drug. 
These characteristics can either be a benefit or a drawback for the drugs efficacy. A drugs 
binding mechanism to plasma protein is therefore essential to understand the 
pharmacokinetic, pharmacodynamic and toxicological profile of any drug. 
 
Human albumin is also used therapeutically in hypovolemic states like shock (due to recent 
blood loss), burns or under surgery [72]. This human albumin product was developed under 
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World War II in the treatment of shock among soldiers on the battlefield, but after the peace 
was restored, this treatment strategy was quickly adopted by surgeons in civilian hospitals. 
 
2.11.2 Binding equilibrium 
The binding reaction of a drug to plasma protein can be regarded as the association of drug 
molecules with the plasma protein.  
 
Drug
+
Plasma
protein
Drug-protein
complex
D P DP
 
Ka =
DP
D x P
 
(Equation 1) 
 
The association constant (Ka) will be large for drugs with high protein binding and small for 
drugs with low protein binding. The two primary binding sites provide the albumin molecule 
with a binding capacity of about 1.2 mmol/l. The normal plasma concentration of most drugs 
is much less then 1.2 mmol/l, and the binding sites are therefore far from saturated. This 
reveals that most binding of drugs to albumin are independent of drug concentration [51].  
Drugs that work at plasma concentration where the protein is approaching saturation is very 
sensitive to further increase in the concentration. Because this will leads to an enormously 
grater amount of free drug in the plasma and may cause side effects and possibly intoxication. 
2.11.3 Protein binding prodrugs 
Designing prodrugs that has higher protein binding than its parent drug is a potential to cause 
drug interactions. This is because a drug with high protein binding can cause displacement of 
another drug which also binds highly to proteins and cause side effects or even lack of effect 
due to a faster clearance. However, there are very few examples of clinically important drug-
drug interactions which are exclusively due to displacement of drugs from the plasma protein 
binding sites [6]. Other processes like absorption, hepatic metabolism and renal clearance are 
of far greater importance to the drug to drug interactions then plasma binding displacement 
[74]. Only when the concentration of one of the drug approaches the molar concentration of 
the binding sites substantial displacement will occur. And because most drugs are relatively 
potent, the binding sites are far from saturated. However displacement interactions may be of 
clinical importance if the displaced drug has a small apparent volume of distribution, narrow 
therapeutic index and rapid onset of action. 
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High protein binding of a prodrug favors site directed drug delivery due to increased 
permeability in inflammatory tissue. Invading pathogens, like influenza viruses, causes 
activation of the innate immune response immediately after the infection. This activates a 
cascade of events which include production of pro-inflammatory cytokines. These cytokines 
acts on vascular endothelial cells of the postcapillary venules and causes an increased 
permeability in the area of inflammation [51]. This enhanced vascular permeability in 
inflammatory tissues causes extravasation of macromolecules, including plasma proteins and 
liposomes. Prodrugs with high protein binding would therefore get a specific target effect to 
the inflammatory site. 
This enhanced permeability is also seen in tumor tissue, in addition to enhanced retention and 
the effect has been described enhanced permeability and retention effect (EPR). However, 
enhanced retention is not seen in inflammatory tissue because the clearance of 
macromolecules and lipids from the interstitial space of inflammatory tissue function as 
normal via the lymphatic system. In tumor tissue this clearance via the lymphatic system is 
impaired and enhanced retention is therefore seen [75, 76].  
 
The plasma protein binding is relevant in several different pharmacokinetic models. The 
volume of distribution, Vd, indicates in what compartment the drug will be confined to, tissue 
or plasma. A drug with high protein binding will have a low Vd, because the drug would be 
confined to the plasma compartment to larger extent. This may minimize adverse affects and 
give a targeting of the drug to the inflamed tissue. 
All clearance models have also incorporated the protein binding term. The clearance of a 
protein with high protein binding will be slower than if the drug was found as free, unbound 
drug in the plasma. And again the half life of a drug is dependent on the rate of clearance. So 
higher plasma protein binding leads to lower Vd, lower clearance and longer half life. 
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3 AIM OF THE STUDY 
3.1 MAIN AIM 
The main aim in this thesis is to study different synthesis strategies around some novel 
prodrugs of the neuraminidase inhibitor oseltamivir carboxylate (GS4071). 
 
3.2 SUB AIM 
3.2.1 Hydrolysis of oseltamivir phosphate 
The hydrolysis of oseltamivir phosphate to oseltamivir carboxylate should be studied and a 
condition giving a good yield of oseltamivir carboxylate and a minimum of byproducts should 
be found. 
3.2.2 X-ray crystal structure 
Crystals of oseltamivir phosphate and oseltamivir carboxylate should be grown and used for 
studies to determine the x-ray crystal structure and to verify the final hydrolysis product of 
oseltamivir phosphate. 
 
3.2.3 Selection of pro moieties 
A nontoxic pro moiety with potential use in the design of amid prodrug of oseltamivir 
carboxylate should be chosen and evaluated. A series of different ester of this pro moiety 
should be synthesized and used as potential prodrug candidates. The synthesized amid 
prodrugs should contain a free carboxylic acid which might increase the prodrugs protein 
binding.  
3.2.4 Selection of synthesis strategy 
Different strategies for synthesizing prodrugs of the chosen promoieties should be studied.  
3.2.5 Further studies of the new amide prodrug 
After synthesizing the new prodrugs of oseltamivir carboxylate, potential further studies 
should be outlined. The binding to human serum albumin, stability towards different esterases 
(serum- and hepatic esterases), penetration through cells and different animal model assays 
would be studied. 
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4 RESULTS AND DISCUSSION 
 
4.1 THE PRODRUG STRATEGY 
 
Oseltamivir is the ethyl ester prodrug of oseltamivir carboxylate. Oseltamivir has a high 
bioavailability (75%) in capsule and suspension formulations. The protein binding of 
oseltamivir is 42%, but is of minor importance due to the fast breakdown of hepatic esterases. 
The active metabolite oseltamivir carboxylate has a very low protein binding of less than 3%. 
By synthesizing some new prodrugs of oseltamivir carboxylate which has a higher protein 
binding, this new prodrug might have many advantages in proportion to oseltamivir. 
 
 
A higher protein binding might lead to: 
 a prolonged duration of action, due to sustained release effect of albumin bound drug 
⁫ improvements in the patients acceptance and compliance, decreased 
administration of doses 
 improved organ selectivity, because of the enhanced permeability in inflammatory 
tissue 
 marketing considerations 
 
 
In this thesis, different coumarin prodrugs of oseltamivir carboxylate were attempted 
synthesized. From the theory, these prodrugs would have a higher protein binding due to more 
hydrophobic characteristics and a free carboxylic group. Coumarin is also a well studied 
compound which is nontoxic. These coumarin prodrugs take advantage of an intramolecular 
lactonization, which rapidly convert the prodrug back to oseltamivir carboxylate and 
coumarin. 
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Table 2 Expected logP values for some of the potential coumarin prodrugs2 
 
 
 
 
Table 2 indicates the expected logP values for some of the potential coumarin prodrugs. 
According to Lipinski et al. compounds with logP values below 5 can be expected to have a 
good absorption and permeation. In addition the compounds should not have more then five 
hydrogen bond donors, molecular weight under 500 and not more then 10 hydrogen bond 
acceptors [77]. These prodrugs have a free carboxylic group and their binding to albumin 
have to be measured in albumin binding assays. A compound with low CLogP and a free 
carboxylic acid might just as well have a higher protein binding then one with higher CLogP 
which lack a negative charge in vivo. This would have been investigated if the prodrugs had 
been synthesized. 
 
 
Structure search in the database SciFinder® Scholar™ of different analogs of oseltamivir 
carboxylate revealed that coumarin prodrugs of oseltamivir carboxylate has never been 
synthesized before. Only 14 compounds were found, 7 amid prodrugs and 7 ester prodrugs 
(Table 2 below). Most of these compounds, except compound number II (oseltamivir) and IX, 
exist only in patents. Because these patents were written in Japanese, further studies around 
whether these compounds have been synthesized or not became very difficult.
                                                 
2
 CLogP values are calculated from ChemDraw Ultra 10.0 
  CLogP 
Oseltamivir 2.13 
Oseltamivir carboxylate 
(deprotonated) -1.43 
R = -CH3 0.43 
R = -CH2CH3 0.96 
R = -C6H6 2.56 
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 Table 3  Known substances of oseltamivir carboxylate3 
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3
 Based on structure search in SciFinder® Scholar™, September 2006 
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4.2 SYNTHESIS OF OSELTAMIVIR CARBOXYLATE 
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The ethyl ester of oseltamivir can be cleaved to the carboxylic acid oseltamivir carboxylate in 
both aqueous base and aqueous acid. Hydrolysis of oseltamivir gives the active metabolite 
oseltamivir carboxylate and ethanol. 
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Figure 30 Degradation pathways for oseltamivir [58] 
 
The pathways for the degradation of oseltamivir in aqueous acid solution have been described 
by Oliyai et al. (Figure 30). Two degradation pathways were identified for oseltamivir, the 
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N,N-migration of the acyl group (yielding isomer 1) and the ethyl ester hydrolysis (yielding 
oseltamivir carboxylate) Because oseltamivir is prone to acyl migration under acid condition 
[78], the formation the degradation products  isomer 1 and 2 develop in addition to 
oseltamivir carboxylate. Unlike the degradation study in Oliayi et al., this thesis hydrolysis of 
oseltamivir was preformed at room temperature and not at 70 ºC. The 3D structure of  
oseltamivir was studied in the program Gauss View 
3.07, after optimizing the structure with MM2 force 
field in Chem3D 10.0. The amino group (atom 
number 1) and the acyl group (atom number 2) were 
rotated into their closest direction (Figure 31). Even 
though they are rotated as close as possible they did 
not get any closer than ≈ 2.95 Å, this is because they 
are in trans positions. 
This explains why hydrolysis at room temperature 
might not have the same problem with acyl 
migration as hydrolysis at 70 ºC, because less kinetic 
energy is available at room temperature to overcome 
the activation energy for acyl migration. 
Results from HPLC and NMR analysis confirm that 
acyl migration is not any problem in the room 
temperature hydrolysis. 
 
Figure 31 Oseltamivir 
The amino group and the acyl group of oseltamivir are rotated into their closest direction. The 
numbers shows the amino nitrogen (1) and the carbonyl carbon (2). 
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Figure 32 shows the pH rate profiles described in Oliyai et al. This figure indicates that pH 4 
would give the lowest value for k2, which increases for more acidic and more basic values. 
The degradation reactions of oseltamivir would go more extensively towards the side 
reactions at pH 4 (Figure 30 above). 
 
In this thesis, the hydrolysis was preformed at pH < 2. A 
hypothetic extrapolation of the rate constants down to 
values below pH 2, at ambient temperature, the k2 might 
increase to a level fare above k1 and k -1. 
 
Acid condition for the hydrolysis of oseltamivir was 
therefore chosen for the first attempt. 
 
 
 
 
 
Figure 32 Plots of the pH rate profiles 
 for the isomerization (k1 and k -1) and ester 
 hydrolysis (k2) of oseltamivir at 70 °C[58]. 
 
 
RESULTS AND DISCUSSION 
54 
4.2.1 Selection of acid concentration 
Studies of aqueous acid hydrolysis of oseltamivir phosphate were made with three different 
concentrations of HCl, 15%, 25% and 32%. These studies revealed that 25% HCl gave the 
highest relative absorbans of oseltamivir carboxylate and lowest absorbans of impurities. Use 
of stronger acid than 25 % only increased the absorbans for impurity, while hydrolysis with 
weaker acids gave a decreased absorbans of oseltamivir carboxylate (Figure 33).  
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Figure 33 Diagram showing the absorbans of oseltamivir carboxylate 
  after 24h of aqueous acid hydrolysis4.  
 
4.2.2 Selection of reaction time for the hydrolysis 
After chosen the acid concentration for the hydrolysis, the reaction time was investigated. 
The hydrolysis of oseltamivir phosphate was studied over 5 days in 25 % HCl (Figure 34 
below).  These studies indicated that the HPLC peak of oseltamivir carboxylate increased 
over time and after 5 days over 50% of the oseltamivir phosphate was hydrolyzed. The 
reaction time was therefore chosen to 5 days, which gave the highest relative absorbans of 
oseltamivir carboxylate. 
                                                 
4
 Diagram based on results from HPLC analysis.  
   Absorbans measured on HPLC (G1) at 230 nm. 
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Figure 34 Acid hydrolysis of oseltamivir phosphate over time5 
 
After several attempts to purify the oseltamivir carboxylate that had been hydrolyzed over  
5 days, it revealed that even though this reaction time might have given the highest relative 
absorbans of oseltamivir carboxylate in the HPLC assay, the product was very difficult to 
isolate. Oseltamivir has probably been broken down to undetectable products in the HPLC 
assay (view point 4.2.4 below). Purification of oseltamivir carboxylate after just 1 day of 
hydrolysis solved this problem, so further hydrolysis were neutralized and purified after 1 day 
reaction time (further described in section 4.2.3 below). The yield of purified product is well 
comparable with the relative absorbance in the HPLC assay after 1 day of hydrolysis. 
 
 
4.2.3 Purification of oseltamivir carboxylate 
The purification of oseltamivir carboxylate was preformed by preparative HPLC after 5 days 
hydrolysis. The analytical HPLC showed that the oseltamivir carboxylate were sensitive to 
eluents with HCOOH (aq), so further attempts to separate the peaks were done with just H2O 
in the eluent. Formic acid pH 3 (HCOOH (aq)) in the eluent protonates the amine group and 
the molecule is positive charged. The molecule had therefore no retention time on in the 
HPLC assay and was washed out together with the eluent, a neutral eluent was therefore used. 
Even though the analytical HPLC showed symmetrical and well separated peaks with 
ACN/H2O (1:9), the purification process on the preparative HPLC gave no yield. 
                                                 
5
 Diagram based on results from HPLC analysis of several studies.  
   Absorbans measured on HPLC (G1) at 230 nm. 
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Attempted eluents: 
- ACN/H2O (1:9) 
- ACN/Ammonium acetate, 0.05 M (aq) (1:9) 
- ACN/Hydroxylamine, 3 % (aq) (1:9)  
 
Neither of these eluents was successful and the yield after purification was approximately 
equally to 0. The eluent with hydroxylamine gave fractions with product, but further analysis 
on HPLC showed a peak with shorter retention time than oseltamivir carboxylate. This 
indicates that something might have happened under the purification process and that 
oseltamivir carboxylate might not be stable in solutions with hydroxylamine.  
Purification of oseltamivir carboxylate with ammonium acetate in the preparative HPLC 
eluent gave a small amount of product, but less than acceptable. Even though this purification 
procedure has been described by Oliyai et al, it did not work in this case. And if it had 
worked, the collected eluent from this purification had to be freeze dried twice to remove the 
excess amount of the ammonium acetate salt [58]. 
 
After several attempts to purify oseltamivir carboxylate that had hydrolyzed for 5 days, new 
attempts were made with reactions products that had just been hydrolyzed for 1 day. 
These reaction products revealed different characteristics and the yield after preparative 
HPLC was much better. Overall, the yield from purification with ACN:H2O (1:9) was 
approximately 47 %. This yield also correlates to the relative absorbans measured in the 
HPLC analysis of the reaction mixture. 
4.2.4 Degradation products of oseltamivir phosphate 
The hydrolysis of oseltamivir phosphate to oseltamivir carboxylate in 25 % HCl can result in 
degradation to other unwanted products. 
O
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O
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2) Ether cleavage ( )
3) Amide hydrolysis ( )
4) Addition of HCl to the alkene ( )
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5) Cis - trans isomerization ( )
6) Acyl migration ( )
 
Figure 35 Possible degradation reactions that can occur of oseltamivir phosphate under 
 acid condition (red = chromophore group) 
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As shown in the figure above, there are several different reactions that can occur under acid 
condition:  
1) Ester hydrolysis 
 This is the wanted reaction, which yield the oseltamivir carboxylate. 
2) Ether cleavage 
 Under very acid conditions, the ether group can be cleaved to give two alcohol  
 molecules. 
3) Amide hydrolysis 
 Hydrolysis of the amide gives an amine and a carboxylic acid. 
4) Addition of H2O or HCl to the alkene 
5) Cis – trans isomerization 
 Isomerization of the stereo centers can occur under acid condition. 
6) Acyl migration 
 Acyl migration has been described in the literature for acid condition at 70 ºC. 
7) Polymerization 
  
In a HPLC assay with neutral eluent, for example ACN:H2O (1:9), all these degradation 
pathways can be detected, except reaction number 4. All the compounds will have different 
retention time and the chromophore group is intact. In reaction 4, the conjugated chromophore 
group is lost. Absorbtion from the carbonyl double bond is best observable when it is 
conjugated with another double bond. Saturated carboxylic acids have weak absorbans around 
200-215 nm, with a molar absorptivity (ε) of about 30-100, therefore the absorption often 
goes unnoticed. Conjugated acids show much stronger absorptions, one C=C double bound 
conjugated with the carboxyl group results in a spectrum with λmax still around 200 nm, but 
with molar absorptivity of about 10,000 [79].  
 
   
  λmax = 200 - 215 nm ε = 30-100 
 
  λmax = 200 nm  ε = 10,000 
 
 Figure 36  Molar absorptivity of different carboxylic acid 
 
 
 
OH
O
OH
O
RESULTS AND DISCUSSION 
58 
All these 7 reactions can be verified by NMR. Reaction 5 which gave isomerization can be 
detected by analyzing the couplings constant in the 1H NMR spectra.  
 
In the analytical HPLC assay used in the experimental section, I1, all compounds with longer 
retention time then 10 minutes were not detected, neither were compounds without the 
chromophore group. 
 
4.2.5 Summary of the chosen strategy for hydrolysis of oseltamivir phosphate 
O
O
O
NH3
NH
O
OH
O
O
NH2
NH
O
Oseltamivir phosphate Oseltamivir carboxylate
GS 4071
Ro 64-08702
25 % HCl
24 h
+ H2PO4-
 
The hydrolysis of oseltamivir was preformed with 25% HCl for 24 hours. 
ACN:H2O (1:9) was chosen as eluent for the purification on preparative HPLC. The fractions 
with retention time of 4.6 minutes (I1) was collected and further analyzed by NMR and MS. 
The analyze results from NMR and MS revealed that the isolated product was pure 
oseltamivir carboxylate.  
 
To verify that the stereo centra are preserved, the couplings constant in the 1H NMR spectra 
was analyzed. The protons in the three stereo centra coupled with each other with 8 Hz, 
indicating cis configuration, and 10 Hz, indicating trans configuration (Coupling constant 
values are found in 6.6.1 Synthesis of oseltamivir carboxylate below). 
 
 
NMR and MS spectra: APPENDIX D on page 106 
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4.3  CRYSTALLOGRAPHIC STUDIES 
 
The background for this study is that search after oseltamivir phosphate and oseltamivir 
carboxylate in Cambridge Structural Database gave no hits. The crystal structure of these 
compounds is therefore not known. In addition to the NMR analysis of oseltamivir 
carboxylate, the x-ray crystallography can confirm lack of acyl migration and retention of 
configuration in the stereo centra. 
Growth of crystals is a time consuming process and there are several criterion to the crystals 
morphology before single crystal x-ray crystallography data could be collected. And hence the 
major limitation to the quality of single-crystal data is crystal quality.  
Two different strategies were attempted to produce crystals from both oseltamivir phosphate 
and oseltamivir carboxylate. 
 
 
Method 1 
Oseltamivir phosphate and oseltamivir carboxylate was dissolved in three different solvents in 
open vials. The solvent was allowed to evaporate, leaving the solid behind. This method gave 
a useless amorphous solid which could not be further analyzed by x-ray diffraction. 
 
 
Table 4 Attempt to grow crystals by method 1 
 No crystals from this method were obtained. 
 
 
Solvent 
Oseltamivir 
phosphate 
Oseltamivir 
carboxylate 
H2O - - 
Methanol - - 
Ethanol:methanol (1:1) - - 
 
 
Method 2 
Oseltamivir phosphate and oseltamivir carboxylate was dissolved in a small amount of water 
in a tiny tube. The tube was capped and one little hole was made in the sealing. The tube was 
then placed in a bigger glass, filled with precipitant and capped. The precipitant evaporated 
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over in the small tube and reduced oseltamivir phosphate and oseltamivir carboxylates 
solubility, until it eventually began to grow crystals.  
 
 
 
 
 
 
 
 
 
 
Figure 37 Crystallization of oseltamivir (OTV) phosphate and oseltamivir carboxylate 
(OTV-C) by method 2 
 
After 2 weeks there was observed crystal growth in two glasses. Oseltamivir phosphate 
crystals had grown in the glass with acetonitrile as precipitant and oseltamivir carboxylate 
crystals had grown with acetone as precipitant. These crystals were further studied in the 
microscope, but their quality was not good enough to obtain x-ray crystallographic data. The 
crystals grown were needle shaped and the needle grains had connected with each other to 
form a continuous network. The needles were also very small, less then 10 µm in diameter. 
The diameter of a good crystal should be approximately 30 µm. 
 
Table 5 Growth of crystals by method 2 
 Crystal formation was observed in two glasses (indicated with + ) after 2 weeks. 
 
 
Precipitant 
Oseltamivir 
phosphate 
Oseltamivir 
carboxylate 
Acetone - + 
Acetonitrile + - 
Ethanol - - 
Isopropanol - - 
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4.4 SYNTHESIS OF THE COUMARIN BASED PRODRUG 
 
To produce a coumarin based prodrug of oseltamivir carboxylate, a key intermediate had to be 
synthesized (Figure 38).  
 
Three different strategies for synthesizing this key  
intermediate are described in the literature [80].  
 
Strategies: 
1) Synthesis from coumarin 
2) Photoisomerization of cinnamic acid 
3) Catalytical hydrogenation of an alkyne 
 from benzofuran-2-carboxylic acid or 
 2-iodophenol 
Figure 38     The key intermediate in the     
     synthesis of coumarin 
   prodrugs 
 
The compounds in this thesis are numbered after their origin, except for equally structures 
which are equally numbered. Compounds from strategy 1 are numbered from 11-17, strategy 
2 compounds from 21-24 and strategy 3 compounds from 31-37. 
4.4.1 Synthesis from coumarin 
The first strategy attempted was to synthesis the key intermediate for the commercially 
available coumarin through a sequence of reactions (6 linear steps). The procedure for this 
reaction was described by Wang et al. (1996) and was used in attempt to synthesize the key 
intermediate. 
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Figure 39 Synthesis from coumarin 
(A more detailed scheme can be found in appendix A below.) 
4.4.1.1 Reaction I, synthesis of compound 12 
The first step in the synthesis was to reduce coumarin to the open ring with a diol by using 
lithium aluminum hydride (LAH). This synthesis is described in the literature [63]. Coumarin 
was dissolved in ether and LAH was added. After stirring for 15 min on an ice bath, the 
reaction mixture was acidified with 1 M HCl. The mixture became a dark yellow emulsion. 
Already at this point something had obviously gone wrong, because the solution was 
supposed to be extracted with ether. This was not possible and addition of ether just gave a 
larger amount of emulsion. The acidifying of the solution is an important step, because a 
longer reaction time than 15 min, would lead to formation of the over reduced product 
without the exo double bond. This had probably happened, since the pH after the addition on 
acid still was basic (~ 9-10). More acid was added, but the mixture remained an emulsion. 
Even though some of the product might have been over reduced, attempts were made to 
purify the whole emulsion by preparative HPLC after evaporation. This was not successful, 
and modification of the procedure had to be made. 
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Figure 40 Synthesis of compound 12 
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Several attempts in accordance with the literature revealed that the acidification step had to be 
modified. A stronger acid, 5 % HCl instead of 1 M HCl, became the solution. This was 
attempted since the described amount of acid not was sufficient to acidify the solution. This 
gave two separated layers, which were extracted with ether. Under the addition of acid, the 
solution got back its yellow color, which gradually disappeared, until the solution was only 
light yellowish. This also indicated than the pH of the solution was acid. After extraction of 
the solution with ether, the combined ether layers was dried and evaporated. The residue was 
easily dissolved in a small amount of ACN and purified by preparative HPLC. 
The mean yield of compound 12 was approximately 44% in all the successful attempts. 
 
4.4.1.2 Reaction II, synthesis of compound 13 
 
Compound 13 was synthesized as described in Wang et al. [63]. This was a straight forward 
procedure which stirred for 14 h. 4-Dimethylaminopyridine (DMAP) was added as a catalyst 
for the reaction (Figure 41 below). tert-Butyl-dimethylsilyl (TBDMS) chloride was used as 
protective group for the primary hydroxyl group. The TBDMS attached selectively to the 
primary hydroxyl group by controlling the reaction time, more than 14h stirring would give 
the side product with TBDMS attached to both the primary and the phenol hydroxyl group. 
The mean yield of compound 13 in all the studies done was ~ 45 %. 
 
This yield was some lower than described in the literature (83 %). One difference from the 
literature procedure that might have affected the yield of the reaction was the temperature. 
The reaction mixture was placed on an ice bath to keep the temperature at 0 °C and stirred 
over the night. The temperature was not kept at 0 °C for all the 14 hours, because the ice 
gradually melted and the temperature of the reaction rose. This might be one of the reasons 
for the lower yield in this reaction. 
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Figure 41 Mechanism for DMAP as catalyst 
 
4.4.1.3 Reaction III and III
 
’, synthesis of compound 14a and 14b 
 
Compound 14a and 14b was synthesized in similar manners, both as described in Wang et al., 
and with acetic anhydride and propionic anhydride as reagent, respectively. DMAP and 
triethylamine (TEA) was added as catalysts. In the literature procedure (Wang et al.), the 
reaction stirred for 1 h under N2 atmosphere. In process analysis of the reaction mixture on 
analytical HPLC revealed that 15 minutes was a sufficient reaction time.  
The mean yield for reaction III was ~ 58 % and for reaction III’ ~ 69 %. 
The compounds were purified by preparative HPLC with an acid free eluent, to avoid 
cleavage of the protection group and the ester.  
4.4.1.4 Reaction IV and IV ’, synthesis of compound 15a and 15b 
In reaction IV and IV’ the TBDMS protective group of the primary hydroxyl was cleaved. 
This was easily done under acid conditions, because TBDMS is relatively sensitive to acid 
[81]. In the literature the reaction stirred for 3h. This time was shortened, because after 3h the 
ester in the molecule also got cleaved. By in process HPLC analysis of the reaction, 1h 
revealed to be a sufficient reaction time. The mean yield for reaction 15a was 84 %.  
The yield of compound 15b after purification was approximately 0 %, because of the very 
small amount of starting material. But results form HPLC analysis confirmed that 15b most 
likely had been synthesized. No further attempts were made to synthesize 15b, because all 
resources were used to optimize the synthesis of compound 15a to compound 17a. 
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4.4.1.5 Reaction V, synthesis of compound 16a 
In reaction V compound 15a was oxidized to compound 16a by pyridinium chlorochromate 
(PCC). PCC was first described by Corey et al. and it was developed especially for the 
oxidation of primary alcohols to aldehyde [82]. The reaction was preformed under dry 
condition as described in the literature [63]. The byproduct (Cr3+) of the reaction deposits with 
pyridine and gave a sticky black tar. This reaction was only synthesized successfully once, at 
the first attempt. Because only 1H-NMR analyses was preformed on the first reaction, and 
later attempts were unsuccessful, this compound lacks 13C-NMR data. 
This product might also have oxidize further to the carboxylic acid under the preparative 
purification process because present oxygen. Analysis for the carboxylic acid was not done. 
 
4.4.2 Photoisomerization of trans-2-hydroxycinnamic acid 
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Figure 42 Synthesis of the key intermediate (compound 17)  
by using a photochemical approach 
 
The photochemical isomerization of trans cinnamic acid have received considerable attention, 
and for almost 100 years ago there was observed formation of small amounts of the cis-isomer 
in experiments were trans cinnamic acid was exposed to sunlight [83]. This photochemical 
approach takes advantage of the known trans to cis photoisomerization of cinnamic acid. The 
cinnamic acid was photolyzed at 365 nm, because studies have shown that long UV 
wavelength favores the trans to cis isomerization and  shorter wavelengths favores the cis to 
trans isomerization [80, 84, 85]. Generally, the cis alkene is less stable than their trans 
isomer, because of steric hindrance.  
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4.4.2.1 Synthesis of compound 22a and 22b 
Compound 22a and 22b was synthesized as described in Zheng et al. [80]. This was a straight 
forward synthesis with an high overall yield. TEA and DMAP were added as catalysts. After 
stirring for 2h, the reaction mixture was washed with 1M HCl, and this removed both DMAP 
and TEA. The mean yield of compound 22a and 22b was approximately 95 % in all 
experiments. 
 
Compound 22a is a commercial available chemical. This compound was rather synthesized 
than bought because: 
- the synthesis from compound 21 was straight forward with a very high yield 
- compound 21 was available in the laboratory and cheaper 
 
4.4.2.2 Synthesis of compound 17a and 17b by photoisomerization  
Compound 22 was dissolved in methanol and placed under two UV lamps for irradiation at 
365 nm. In Zheng et al., 24h of irradiation gave an yield of approximately 75 % for 
compound 17a [80]. In this thesis experiments a much longer irradiation time was necessary. 
After 48h only ~ 9 % of the trans isomer was converted to cis, based on 1H NMR analysis. 
The cis isomer was isolated by preparative HPLC. 
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Figure 43 Photoisomerization of compound 22a and 22b to 17a and 17b, respectively6. 
 
 
                                                 
6
 Diagram based on results from HPLC analysis.  
   Absorbans measured at 250 nm. 
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The figure above indicates that the photoisomerization of compound 22 is a time consuming 
process. And several days was necessary to yield a satisfaction conversation of the trans 
isomer. The literature described a much higher yield and a much shorter reaction time for this 
synthesis. The reason for this must be the equipment. The UV-lamps that were used in this 
thesis experiments was not designed for photochemistry, which Zheng et al. most likely had. 
The power level of the UV-lamp is also of importance. Wang et al. have described that low 
power UV lamps (4 W) are favored over higher powered, e.g. 500 W, UV lamps [84]. In this 
thesis it was used two low powered hand held UV lamps, one with 6 W and one with 12 W 
power. Higher powered lamps were associated with potential photochemical side reactions. 
Many unknown factors may have influenced this reaction, but most of them must relate to the 
equipment. The hand held UV lamps used were not designed for photochemistry, but for TLC 
plate viewing, fluorochemistry, food inspection, quality control, titration, pesticide analysis 
and mineralogy [86]. Special equipment, e.g. glassware and apparatus, for photochemical 
reactions can be bought from commercial institutions, but due to the limited time this was not 
further investigated or bought. 
4.4.2.3 Attempted synthesis of compound 23a and 23b 
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The synthesis of acid anhydride was attempted with use of 0.5 eq dicyclohexylcarbodiimide 
(DCC). Synthesis of acyclic anhydride are known to be difficult to prepare directly from the 
corresponding acids [87]. But use of DCC as couplings agent have been used successfully by 
others on the Department of Pharmaceutical Chemistry, so it was made an attempt to make 
this acid anhydride. This synthesis was not successful, the 1H NMR and 13C NMR analysis 
showed no signal from the product. This might be because this compound has sp2 
configuration α to the carbonyl, which also is conjugated with a benzene ring and this might 
complicate the synthesis.  
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4.4.2.4 Attempted synthesis of compound 24b 
Acid chlorides are more reactive than acid anhydrides and are relatively easy to prepare. The 
carboxylic acid was therefore converted into an acid chloride by treatment with oxalyl 
chloride, other agents, like thionyl choride, could also have been used. A catalytic amount of 
dimethylformamide (DMF) was added and the reaction was monitored by HPLC (G1) 
analysis. 
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Figure 44 Synthesis of the acid chloride 24b 
 
Since acid chlorides are too reactive to be monitored itself, the formation of the methyl ester 
of compound 24b was observed instead. 1 droplet of the reaction mixture was added 1 ml 
methanol in an HPLC vial. The acid chloride reacted immediately with methanol to give the 
methyl ester of compound 24b (Figure 45). To ensure that all acid chloride molecules had 
reacted, a small amount of water was also added. The observation of methyl ester based on 
the principle that the methyl ester of compound 24b had a longer retention time than 
compound 17b, 9.0 minutes compared to 7.1 minutes respectively, and could therefore be 
used as an indicator for the formation of acid chloride.  
O
O O
O CH3
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Figure 45 The synthesis of acid chloride was monitored by  
HPLC analysis of the methyl ester of compound 24b 
 
The HPLC analysis indicated that the acid chloride was synthesized. Because a surplus of 
oxalyl chloride had been used and this reaction generates 1 molecule of acid (HCl), the 
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reaction was to acid for the ester in the product, which decomposed under the careful 
evaporation.  
 
Due to small amounts of the reactant, long reaction time of the photoisomerization and lack of 
time, attempts to optimize this procedure were not done in this thesis. 
 
4.5 ALTERNATIVE STRATEGIES NOT ATTEMPTED 
 
4.5.1 Catalytical hydrogenation of an alkyne 
This strategy was not attempted in practice, but is mention as an alternative to the two other 
strategies above. The strategy takes advantage of known literature procedures to convert 
benzofuran-2-carboxylic acid (compound 31) or 2-iodophenol (compound 32) into 3-(2-
hydroxyphenyl)propynoic acid (compound 33) as described in Figure 46 [80, 88, 89, 90, 91].  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 46 The catalytical hydrogenation approach 
 
Synthesis from compound 31 [80] 
Compound 33 can be synthesized from compound 31 as described in Zheng et al. After 
purification this reaction had an 89 % yield. Compound 33 is further treated with acid 
anhydride, to give compound 35 with above 80 % yield. Compound 35 can either be 
hydrogenated in the presence of Lindlar catalyst and purified to give compound 36 (yield 77 
%) before it is coupled with oseltamivir carboxylate or the coupling with oseltamivir 
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carboxylate can be synthesized first, compound 37,  and then hydrogenated to yield the 
coumarin prodrug. Each step will be purified by preparative HPLC. 
 
Synthesis from compound 32 
The synthesis of compound 33 and 35 from compound 32 and 34, respectively, is achieved 
through a sonogashira reaction. This can be preformed by a similar synthesis strategy as 
described in Hadfield et al. or Pal et al. [89, 91]. Compound 34 is synthesized by treating 
compound 32 with an acid anhydride before the sonogashira reaction. 
Compound 35 is treated in the same matter as described above for the syntesis from 
compound 31. Each compound will be purified by preparative HPLC before further synthesis. 
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4.5.2 Synthesis of the cinnamic acid succinimido ester 
 
cinnamic succinimido ester
 
Figure 47 Alternative approach to synthesize the coumarin prodrug 
 
This approach is an additional alternative for the coupling of acid chloride with the 
oseltamivir carboxylate. Compound 24 is first coupled with N-hydroxysuccinimide in a 
nonpolar solvent, add triethylamine as catalyst. Then the literature procedure described in 
McCafferty et al is used for coupling of oseltamivir carboxylate to this cinnamic succinimido 
ester [92]. In this procedure trichloroethaol must be used instead of DMF as solvent because 
of the solubility problem with oseltamivir carboxylate in non polar solvents.  
 
Table 6 Solubility of oseltamivir carboxylate 
Milligram quantities of oseltamivir carboxylate was dissolved in 1 ml solvent and stirred in 
the ultrasound bath.  
 
Solvent Dissolved? 
Acetone No 
ACN No 
ACN:DCM (1:1) No 
ACN:THF (1:1) No 
Chloroform No 
DCM No 
DMF No 
DMSO No 
H2O Yes 
Methanol Yes 
Pyridine Yes 
Tetrahydrofurane No 
Trifluorethanol Yes 
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5 CONCLUDING REMARKS 
 
The hydrolysis of oseltamivir phosphate to its active metabolite oseltamivir carboxylate was 
studied under different acid condition. These studies indicated that hydrolysis in 25 % HCl for 
1 day gave the best yield of oseltamivir carboxylate. 
 
The aim in this thesis was to study the synthesis around some novel prodrugs of oseltamivir 
carboxylate with potential higher protein binding to albumin then its parent compound 
oseltamivir carboxylate. Coumarin was chosen as pro moiety for these compounds. The major 
advantage with coumarin is that it has been studied for many years and the toxicity profile is 
therefore well known. These prodrugs should contain a free carboxyl acid which binds to 
albumin and ensures that the overall molecule is not to hydrophobic. According to Lipinski et 
al. a drug would have poor absorption and penetration if the molecule has more then five 
hydrogen binding donors, molecule weight over 500, log P over 5 and has more then 10 
hydrogen binding acceptors [77]. 
 
The coumarin prodrugs are based on the pro prodrug concept. The pro pro moiety is cleaved 
by esterase in vivo and thereby the amid bound prodrug takes advantage of the facile 
lactonization of cinnamic acid which restore the parent drug and a nontoxic coumarin moiety. 
The coumarin prodrugs have to be tested in many different assays to clarify its kinetic and 
targeting effect. The obviously advantage to synthesize these prodrugs is that they might have 
higher protein binding then oseltamivir which has only an ethyl ester as pro moiety. 
 
Two different strategies were attempted to synthesis the key intermediate for the coumarin 
prodrug of oseltamivir carboxylate. The first strategy was to make the prodrug moieties from 
the cheap and commercially available coumarin and the second strategy was to synthesis the 
key intermediate trough a photochemical approach.  
 
The synthesis from coumarin was chosen for the first attempt, but because this synthesis 
required a long sequence of reactions (6 linear steps) with a low overall yield, the key 
intermediate became difficult to develop. Even though several attempts were made, improved 
synthesis and larger scale, the final key intermediate was not synthesized from this strategy. 
The photochemical approach gave the key intermediate, but not in time and not in sufficient 
amount to do a successful coupling to oseltamivir carboxylate. 
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Two alternative synthesis strategies have been suggested to synthesize the key intermediate 
and to optimize the coupling of the promoiety to oseltamivir carboxylate. If there had been 
more time these approaches would have been attempted. There were also further plans for 
testing of the synthesized coumarin prodrug if they had been synthesized. 
 
The coumarin prodrugs are design to have a higher protein binding to human serum albumin 
than oseltamivir and avoid complete hydrolysis by first pass metabolism. The plan was to 
study different prodrugs in assays with human serum, were the combined effect of protein 
binding and the breakdown profile by esterase is observed. The breakdown profile by 
different esterases, for example hepatic esterases, is also an interesting approach. In addition, 
possible binding sites for these prodrugs on albumin could also have been investigated. 
Animal studies might be preformed to investigate the targeting effect of these new prodrugs. 
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6 EXPERIMENTAL 
 
6.1 MATERIALS AND METHODS 
 
6.1.1 Reagents 
 
Water:   Elga PureLab Maxima HPLC  
   (ion exchanged, HPLC-grade water) 
 
Other reagents: APPENDIX E 
6.1.2 Solvents 
6.1.2.1 Solvents for synthesis 
Refers to APPENDIX E 
6.1.2.2 Solvents for HPLC-analysis 
HPLC-grade quality from commercial institutions (Fluka, Sigma-Aldrich, Merck, Kebo-Lab, 
Riedel-de Haën). 
 
6.1.2.3 Deuterated solvents 
Chloroform-d (CDCl3), 99.8 atom % D:    Aldrich 
(methylsulfoxide)-d6 (DMSO-d6), “100” (min. 99.96 atom % D):  Aldrich 
Methanol-d4 (CD3OD-d4), 99.8 atom % D:    Aldrich 
Deuterium oxide-d2 (D2O), 100 atom % D:    Aldrich 
 
6.1.3 Solutions 
6.1.3.1 Formic acid solution pH 3 
0.46 g of formic acid was diluted to 1 liter with purified water, giving a concentration  
of 10 mM. 
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6.1.4 Solvents for NMR 
1H and 13C NMR were recorded on a Bruker Avance DPX 300 instrument, at 300 MHz and 
75 MHz respectively. All experiments were performed at 25 °C with deuterated solvents. 
 
Reference peaks [93]: CDCl3:  1H δ 7.25  13C δ 77.0 
   DMSO-d6: 1H δ 2.5  13C δ 39.7 
   MeOH-d4: 1H δ 3.35  13C δ 49.0 
    
 
6.2 HPLC ANALYSIS 
 
6.2.1 Apparatus 
Technical details 
Autosampler:   HP G1313A 
Pump:    HP Aglient 1100 series binary pump 
Coloumn:   C18 250 x 2 mm, 5 µ particle size, Luna, 
    Phenomenex 
Detector:    HP G1315A Diode Array Detector 
Data acquisition and handling: HP Chemstation version A.06.03 [509] 
 
Experimental parameters 
Coloumn temperature:  Ambient 
Injection volume:   5 µl 
Flow rate:   0.5 ml/min 
Mobile phase:   Gradient and isocratic 
Chromatogram run time:  14 min and 20 min 
Detection wavelengths:  UV, 317 nm, 210 nm and 250 nm, 
    bond with 16 
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6.2.2 Mobile phase 
Gradient 1 (G1) 
 
 
Time (min) 
Formic acid  
10 mM, pH 3 (%) 
 
ACN (%) 
 
Flow (ml/min) 
0 80 20 0.5 
8 20 80 0.5 
12 20 80 0.5 
14 80 20 0.5 
- 80 20 0.5 
 
Isocratic 1 (I1) 
 
Time (min) 
 
H2O (%) 
 
ACN (%) 
 
Flow (ml/min) 
- 90 10 0.5 
 
This isocratic eluent was used for analyzing the hydrolysis of oseltamivir phosphate. 
 
6.3 PREPARATIVE HPLC 
Technical details 
Injector:    Manual 
Pump:    Modified HP 1050 
Coloumn:   250 x 20 mm packed with LiChropre® RP-18, 
    25-40 µm particles 
Detector:    Labomatic Labcord-200 UV spectrophotometer 
Data acquisition and handling: Absorbance was read from the detector while 
chromatographying 
 
 
Experimental parameters 
Coloumn temperature:  Ambient 
Injection volume:   5-10 ml 
Flow rate:   10 ml/min 
Mobile phase:   Isocratic 
Detection wavelength:  UV, 220 nm and 250 nm 
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6.3.1 Mobile phase 
Isocratic mobile phases were prepared using different volume ratios of ACN and formic acid-
solution pH 3 (HCOOH (aq)) or H2O. Choice of ratio was based on analytical HPLC; the 
isocratic eluent that gave retention times of about 6-8 minutes was chosen as the mobile 
phase. 
 
6.4 UV LAMPS 
 
6.4.1 UV lamp 1 
Technical details 
Producer:   UVItec Limited 
Model:   LF 106L 
Wavelength:  365 nm 
Power:    12 W 
Frequency:  50 Hz  
Voltage:   230 V 
 
6.4.2 UV lamp 2 
Technical details 
Producer:   Vilber Lourmat 
Model:   VL-6.L  
Wavelength:  365 nm 
Power:    6 W 
Frequency:  50 Hz  
Voltage:   230 V 
 
6.5 MICROSCOPY 
Technical details 
Producer:   Zeiss 
Model:   SteREO Discovery.V12 
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6.6 SYNTHESIS 
 
6.6.1 Synthesis of oseltamivir carboxylate 
 
OH
O
O
NH2
NH
O
O
O
O
NH3+
NH
O
25 % HCl
Chemical Formula: C14H24N2O4
Molecular Weight: 284,35
Oseltamivir phosphate Oseltamivir carboxylate
H2PO4-
Chemical Formula: C16H31N2O8P
Molecular Weight: 410,40
 
 
Oseltamivir phosphate (800 mg, 1.95 mmol) was dissolved in HCl (1 ml, 25 %). The solution 
stirred at room temperature over night. After neutralization to pH 7 by Na2CO3(s), the 
solution was purified by preparative HPLC with ACN/H2O (10:90) to afford oseltamivir  
carboxylate as a white solid. 
 
 
Yield:  302 mg (54.1 %)     
 
HPLC:  Rt: 4.6 minutes (I1) 
 
1H NMR (300 MHz, CD3OD): δ 0.91 (q, 6H, J=7.4Hz), 1.53 (m, 4H), 
    2.03 (s, 3H), 2.42 (ddt, 1H, J=2.8Hz, J=10.0Hz, 
    J=17.4Hz), 2.86 (dd, 1H, J=5.5Hz, J=17.4Hz), 
    3.41 (m, 2H), 3.94 (dd, 1H, J=8.2Hz, J=11.0Hz), 
    4.15 (d, 1H, J=8.2Hz), 6.59 (t, 1H, J=2.0Hz) 
     
13C NMR (75 MHz, CD3OD): 9.650, 9.878, 23.207, 26.667, 27.308, 31.138, 51.421, 
    54.881, 76.413, 83.380, 133.337, 134.596, 173.696, 
    174.651 
 
MS (ES+; TOF):   m/z 197.0 (9 %), 285.1 ([M+H]+ = 100 %) 
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6.6.2 Growth of oseltamivir phosphate crystals 
 
Method 1 
 
 
Oseltamivir phosphate (20 mg) was weight out in three small glasses. The three glasses was 
added water (100 µl), methanol (200 µl) and methanol:ethanol (1:1) (1.2 ml), respectively. 
The solution was allowed to evaporate at room temperature over night.  
 
The solid obtained after the solvent had evaporated was observed in the microscope.  
No crystals were observed. 
 
 
 
Method 2 
 
Oseltamivir phosphate (approximately 0.5-2 mg) was weight out in four small tubes and 
dissolved in water (30 µl). The tubes were capped and a little hole was made in the sealing. 
The tubes were then placed in four glasses. Each of the glasses was added precipitant, acetone 
(1 ml), acetonitrile (1 ml), ethanol (1 ml) and isopropanol (1 ml), respectively and closed. 
 
After two weeks, crystal growth were  
observed in the glass with acetonitrile 
as precipitant. The crystals were observed  
in the microscope. The quality of the  
crystal was not good enough for further  
x-ray study. 
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6.6.3 Growth of oseltamivir carboxylate crystals 
 
 
Method 1 
 
 
Oseltamivir carboxylate (20 mg) was weight out in three small glasses. The three glasses was 
added water (100 µl), methanol (200 µl) and methanol:ethanol (1:1) (600 µl), respectively. 
The solution was allowed to evaporate at room temperature over night.  
 
The solid obtained after the solvent had evaporated was observed in the microscope.  
No crystals were observed. 
 
 
 
Method 2 
 
Oseltamivir carboxylate (approximately 0.5-2 mg) was weight out in four small tubes and 
dissolved in water (30 µl). The tubes were capped and a little hole was made in the sealing. 
The tubes were then placed in four glasses. Each of the glasses was added precipitant, acetone 
(1 ml), acetonitrile (1 ml), ethanol (1 ml) and isopropanol (1 ml), respectively and closed. 
 
After two weeks, crystal growth were 
observed in the glass with acetone as  
precipitant. The crystals were observed 
in the microscope. The quality of the  
crystals was not good enough for further  
x-ray study. 
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6.6.4 Synthesis of compound 12,  
(Z)-2-(3-hydroxyprop-1-enyl) phenol 
 
O
O
OH
OH
11
Coumarin
Chemical Formula: C9H6O2
Molecular Weight: 146,14
(Z)-2-(3-hydroxyprop-1-enyl)phenol
Chemical Formula: C9H10O2
Molecular Weight: 150,17
o
LAH,
0 C,
15 min
12
 
 
Coumarin (3.65 g, 25 mmol) was dissolved in ether (100 ml) and placed in a cold bath. 
Then the solution was treated at 0 °C with a solution of lithium aluminum hydride (LAH) 1.0 
M in ether (50 ml, 50 mmol). After stirring for 15 min, 5 % HCl (25 ml) was added to the 
reaction at 0 °C. Then the solution was adjusted to pH 5 with 1M HCl and extracted with 
ether (3x75 ml). The ether layer was dried over Na2SO4. The drying agent was removed by 
gravity filtration and the filtrate evaporated. The residue was then re-dissolved in ACN and 
purified by preparative HPLC with ACN/HCOOH (aq) (25:75) to afford compound 12 ((Z)-2-
(3-hydroxyprop-1-enyl)phenol) as a white solid. 
 
YIELD:    2.41 g (64.3 %) 
 
HPLC:    Rt: 4.6 minutes (G1) 
 
1H NMR (300 MHz, CD3OD): δ 4.26 (dd, 2H, J=6.5Hz), 5.80 (m, 1H), 
    6.63 (d, 1H, J=11.7Hz), 6.79 (m, 2H), 7.08 (m, 2H) 
 
13C NMR (75 MHz, CD3OD): δ 60.19, 116.23, 120.11, 125.07, 127.28,  
    129.72, 131.29, 131.78, 156.10 
    There were some overlapping signals. 
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6.6.5 Synthesis of compound 13,  
(Z)-2-(3-(tert-butyldimethylsilyloxy)prop-1-enyl)phenol [63] 
OH
OH
OH
O
TBDMS
(Z)-2-(3-hydroxyprop-1-enyl)phenol
Chemical Formula: C9H10O2
Molecular Weight: 150,17
(Z)-2-(3-(tert-butyldimethylsilyloxy)
prop-1-enyl)phenol
Chemical Formula: C15H24O2Si
Molecular Weight: 264,44
TBDMS-Cl,
DMAP,
0 C,
14 h
o
12 13
 
 
A solution of compound 12 (3.425 g, 22.8 mmol) was dissolved in dry THF (35.5 ml) and 
placed in a cold bath. To the stirred solution tert-butyl-dimethylsilyl (TBDMS) chloride 
(3.787g, 25.1 mmol) was added at 0 °C. Then N,N-dimethylpyridin-2-amine (DMAP) (4.182 
g, 34.2 mmol) in dry THF (44 ml) was drop wise added. After stirring for 14 h at 0 °C, the 
solution was filtered and evaporated to remove the THF. The residue was re-dissolved in ethyl 
acetate (44 ml) and washed with 1 M HCl (2 x 27 ml), 5 % NaHCO3 (22 ml) and H2O  
(22 ml). The ethyl acetate layer was dried over Na2SO4, filtered, and evaporated. The residue 
was then re-dissolved in ACN and purified by preparative HPLC with ACN/H2O (70:30) to 
afford compound 13 ((Z)-2-(3-(tert-butyldimethylsilyloxy)prop-1-enyl)phenol) as a light 
yellow solid. 
 
YIELD:    3.485 g (57.8 %) 
 
HPLC:     Rt: 13.3 minutes (G1) 
 
1H NMR (300 MHz, CD3OD): δ 0.03 (s, 6H), 0.88 (s, 9H),  4.36 (dd, 2H, J=6.3Hz),  
    5.77 (dt, 1H, J=6.3Hz, J=11.8Hz),  
    6.61 (d, 1H, J=11.7Hz), 6.77-7.07 (m, 4H) 
 
13C NMR (75 MHz, CD3OD): δ -4.99, 19.16, 26.43, 61.72, 116.24, 120.04,  
    125.05, 126.95, 129.73, 131.31, 132.05, 156.10 
    There were some overlapping signals. 
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6.6.6 Synthesis of compound 14a, 
(Z)-2-(3-(tert-butyldimethylsilyloxy)prop-1-enyl)phenyl acetate [63] 
 
OH
O
TBDMS
O
O O
TBDMS
(Z)-2-(3-(tert-butyldimethylsilyloxy)
prop-1-enyl)phenol
Chemical Formula: C15H24O2Si
Molecular Weight: 264,44
(Z)-2-(3-(tert-butyldimethylsilyloxy)
prop-1-enyl)phenyl acetate
Chemical Formula: C17H26O3Si
Molecular Weight: 306,47
Acetic anhydride,
DMAP,
TEA
13 14a
 
To a solution of compound 13 (3.521g, 13.3 mmol) in dry CH2Cl2 (73 ml) was added drop 
wise acetic anhydride (1.5 ml, 15.8 mmol), then DMAP (325 mg, 2.7 mmol) and 
triethylamine (TEA) (3.3 ml, 23.8 mmol). After stirring at room temperature under Ar 
atmosphere for 15 minutes, the reaction mixture was washed with 1 M HCl (2 x 49 ml),  
5 % NaHCO3 (37 ml) and H2O (37 ml). The dichloromethane layer was dried over Na2SO4, 
filtered, and evaporated. The residue was re-dissolved in ACN and purified by preparative 
HPLC with ACN/H2O (70:30) to afford compound 14a ((Z)-2-(3-(tert-
butyldimethylsilyloxy)prop-1-enyl)phenyl acetate) as a white powder. 
 
YIELD:    2.431 g (59.6 %) 
 
HPLC:     Rt: 15.9 minutes (G1) 
 
1H NMR (300 MHz, CD3OD): δ 0.01 (s, 6H), 0.87 (s, 9H), 2.26 (s, 3H), 
    4.29 (dd, 2H, J=1.6Hz, J=6.3Hz),  
    5.88 (dt, 1H, J=6.3Hz, J=11.7Hz),  
    6.40 (dt, 1H, J=1.5Hz, J=11.6Hz), 7.08 (m, 1H), 
    7.24 (m, 2H), 7.33 (m, 1H) 
 
13C NMR (75 MHz, CD3OD): δ -5.05, 19.09, 20.81, 26.37, 61.39, 123.46, 125.37,  
    126.89, 129.80, 131.35, 134.71, 149.76, 171.19 
    There were some overlapping signals. 
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6.6.7 Synthesis of compound 14b, 
(Z)-2-(3-(tert-butyldimethylsilyloxy)prop-1-enyl)phenyl propionate [63] 
 
OH
O
TBDMS
O
O O
TBDMS
(Z)-2-(3-(tert-butyldimethylsilyloxy)
prop-1-enyl)phenol
Chemical Formula: C15H24O2Si
Molecular Weight: 264,44
(Z)-2-(3-(tert-butyldimethylsilyloxy)
prop-1-enyl)phenyl propionate
Chemical Formula: C18H28O3Si
Molecular Weight: 320,50
Propionic anhydride,
DMAP,
TEA
13 14b
 
To a solution of compound 13 (526 mg, 1.99 mmol) in dry CH2Cl2 (11 ml) was added drop 
wise propionic anhydride (0.305 ml, 2.34 mmol), then DMAP (48 mg, 0.39 mmol) and TEA 
(0.5 ml, 3.6 mmol). After stirring at room temperature under Ar atmosphere for  
15 minutes, the reaction mixture was washed with 1 M HCl (2 x 9 ml), 5 % NaHCO3 (7 ml) 
and H2O (7 ml). The dichloromethane layer was dried over Na2SO4, filtered, and evaporated 
to afford compound 14b ((Z)-2-(3-(tert-butyldimethylsilyloxy)prop-1-enyl)phenyl 
propiontate) as a white powder. 
 
YIELD:    443 mg (69.5 %) 
    
HPLC:     Rt: 17.6 minutes (G1) 
 
1H NMR (300 MHz, CD3OD): δ 0.01 (s, 6H), 0.88 (s, 9H), 1.21 (t, 3H, J=7.5Hz),  
    2.58 (q, 2H, J=7.5Hz), 4.29 (dd, 2H, J=1.6Hz, J=6.3Hz), 
    5.87 (dt, 1H, J=6.3Hz, J=11.7Hz),  
    6.39 (dt, 1H, J=1.5Hz, J=11.6Hz),  
    7.06 (d, 1H, J=7.8Hz), 7.23-7.31 (m, 3H) 
 
13C NMR (75 MHz, CD3OD): δ -4.99, 9.47, 19.12, 26.42, 28.29, 61.36, 123.51,  
    125.33, 126.72, 129.70, 130.98, 131.36, 134.87,  
    147.87, 174.13  
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6.6.8 Synthesis of compound 15a, 
(Z)-2-(3-hydroxyprop-1-enyl)phenyl acetate [63] 
 
O
O OH
O
O O
TBDMS
(Z)-2-(3-(tert-butyldimethylsilyloxy)
prop-1-enyl)phenyl acetate
Chemical Formula: C17H26O3Si
Molecular Weight: 306,47
(Z)-2-(3-hydroxyprop-1-enyl)phenyl acetate
Chemical Formula: C11H12O3
Molecular Weight: 192,21
H2O:THF:HOAc (1:1:3)
14a 15a
 
 
To a solution of compound 14a (1.429 g, 4.7 mmol) in THF (13 ml) was added water (13 ml). 
This was followed by the drop wise addition of acetic acid (39 ml). The mixture was stirred at 
room temperature for 1 h and then evaporated to remove THF, water and acetic acid. Ethyl 
acetate (52.4 ml) was added to the residue, which was washed with 5 % NaHCO3 (2 x 26 ml) 
and water (2 x 26 ml). The ethyl acetate solution was dried over Na2SO4, filtered, and 
evaporated. The residue was then re-dissolved in ACN and purified by preparative HPLC 
with ACN/HCOOH (aq) (20:80) to afford compound 15a ((Z)-2-(3-hydroxyprop-1-
enyl)phenyl acetate) as a colorless oil. 
 
YIELD:    48 mg (51.4 %) 
 
HPLC:     Rt: 4.8 minutes (G1) 
 
1H NMR (300 MHz, CD3OD): δ 2.28 (s, 3H), 4.23 (dd, 2H, J=1.4Hz, J=6.7Hz),  
    5.96 (dt, 1H, J=6.7Hz, J=11.5Hz),  
    6.47 (d, 1H, J=11.5Hz),  
    7.05 (dd, 1H, J=1.0Hz, J=7.9Hz), 7.25 (m, 3H) 
     
 
13C NMR (75 MHz, CD3OD): δ 20.76, 59.85, 123.54, 125.32, 125.62, 126.81,  
     126.86, 128.10, 129.72, 149.92, 170.78 
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6.6.9 Synthesis of compound 16a, 
(Z)-2-(3-oxoprop-1-enyl)phenyl acetate [63] 
 
O
OHO
(Z)-2-(3-hydroxyprop-1-enyl)phenyl acetate
Chemical Formula: C11H12O3
Molecular Weight: 192,21
O
OO
(Z)-2-(3-oxoprop-1-enyl)phenyl acetate
Chemical Formula: C11H10O3
Molecular Weight: 190,20
PCC
15a 16a
 
 
To a solution of pyridinium chlorochromate (PCC) (3.9 g, 18.1 mmol) in dry  
CH2Cl2 (201 ml) was added drop wise a solution of compound 15a (1.74 g, 9.1 mmol) in dry 
CH2Cl2 (115 ml) during 20 min. After stirring at room temperature under Ar atmosphere for 
30 min, the black solution was poured onto a short silica gel column and eluted with CH2Cl2 
to remove the chromium salts. The black residue was washed several times with CH2Cl2 and 
the solution was run through the same column. The solution was then evaporated. The residue 
was then re-dissolved in ACN and purified by preparative HPLC with ACN/HCOOH (aq) 
(25:75) to afford compound 16a ((Z)-2-(3-oxoprop-1-enyl)phenyl acetate) as a green oil. 
 
YIELD:    298 mg (17.3 %) 
 
HPLC:    Rt: 7.3 minutes (G1) 
 
 
1H NMR (200 MHz, CDCl3):  δ 2.29 (s, 3H), 6.21 (dd, 1H, J=8.1Hz, J=11.5Hz), 
    7.17 (dd, 1H, J=8.0Hz), 7.32-7.52 (m, 4H), 
    9.81 (d, 1H, J=8.1Hz) 
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6.6.10 Synthesis of compound 22a, 
 trans-3-(2-acetoxyphenyl)acrylic acid [80] 
 
OH
O
OH O
O
OH
O
trans-2-hydroxycinnamic acid
Chemical Formula: C9H8O3
Molecular Weight: 164,16
trans-3-(2-acetoxyphenyl)acrylic acid
Chemical Formula: C11H10O4
Molecular Weight: 206,19
Acetic anhydride,
TEA,
DMAP,
0 oC
21 22a
 
 
Acetic anhydride (299 mg, 2.9 mmol) was added drop wise to a cooled (0 °C) solution of 
compound 21 (400 mg, 2.4 mmol) in anhydrous THF (20 ml) under Ar atmosphere with 
stirring. TEA (541 mg, 5.3 mmol) and DMAP (44 mg, 0.36 mmol) were added successively. 
The mixture was allowed to warm to room temperature and then stirred for another 2 h. After 
solvent evaporation, the residue was dissolved in ethyl acetate (53.5 ml) and washed with 1 M 
HCl (2 × 10 ml). The combined aqueous layer was then extracted with ethyl acetate. The 
organic layers were combined and washed with brine and then dried over MgSO4. The 
solution was then filtered and evaporated to afford compound 22a (trans-3-(2-
acetoxyphenyl)arylic acid) as a white solid. 
 
YIELD:    450 mg (89.6 %) 
 
HPLC:     Rt: 6.5 minutes (G1) 
 
1H NMR (300 MHz, DMSO): δ 2.35 (s, 3H), 6.56 (d, 1H, J=16.1Hz), 
    7.21 (dd, 1H, J=0.8, J=8.1Hz),  
    7.32 (t, 1H, J=7.4Hz), 7.47 (m, 1H),  
    7.54 (d, 1H, J=16.1Hz),  
    7.87 (dd, 1H, J=1.1Hz, J=7.7Hz), 12.52 (s, 1H) 
 
13C NMR (75 MHz, DMSO):  δ 20.54, 121.29, 123.23, 126.35, 126.60, 127.68,  
    131.18, 136.53, 148.89, 167.13, 169.00 
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6.6.11 Synthesis of compound 22b, 
trans-3-(2-(propionyloxy)phenyl)acrylic acid [80] 
 
OH
O
OH O
O
OH
O
trans-2-hydroxycinnamic acid
Chemical Formula: C9H8O3
Molecular Weight: 164,16
Propionic anhydride,
TEA,
DMAP,
0 oC
trans-3-(2-(propionyloxy)phenyl)acrylic acid
Chemical Formula: C12H12O4
Molecular Weight: 220,22
21 22b
 
 
Propionic anhydride (285 mg, 2.2 mmol) was added drop wise to a cooled (0 °C) solution of 
compound 21 (300 mg, 1.8 mmol) in anhydrous THF (22.5 ml) under Ar atmosphere with 
stirring. TEA (407 mg, 4.0 mmol) and DMAP (36 mg, 0.29 mmol) were added successively. 
The mixture was allowed to warm to room temperature and then stirred for another 2 h. After 
solvent evaporation, the residue was dissolved in ethyl acetate (40 ml) and washed with 1 M 
HCl (2 × 10 ml). The combined aqueous layer was then extracted with ethyl acetate. The 
organic layers were combined and washed with brine and then dried over MgSO4. The 
solution was then filtered and evaporated to afford compound 22b (trans-3-(2-
(propionyloxy)phenyl)acrylic acid) as a white solid. 
 
YIELD:    334 mg (83.0 %) 
 
HPLC:     Rt: 7.3 minutes (G1) 
 
1H NMR (300 MHz, DMSO): δ 1.18 (t, 3H, J=7.5Hz), 2.68 (q, 2H, J=7.5Hz), 
    6.55 (d, 1H, J=16.1Hz), 7.21 (dd, 1H, J=1.1Hz,  
    J=8.1Hz), 7.32 (dt, 1H, J=0.7Hz, J=7.4Hz), 
    7.47 (m, 1H), 7.54 (d, 1H, J=16.1Hz),  
    7.87 (dd, 1H, J=1.5Hz, J=7.8Hz), 12.46 (s, 1H) 
 
13C NMR (75 MHz, DMSO):  δ 8.89, 26.83, 121.25, 123.20, 126.32, 126.62,  
    127.68, 131.17, 136.53, 148.91, 167.12, 172.33 
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6.6.12 Synthesis of compound 17a,  
cis-3-(2-acetoxyphenyl)arylic acid [80] 
 
O
O
OH
O
O
O
UV
trans-3-(2-acetoxyphenyl)acrylic acid
Chemical Formula: C11H10O4
Molecular Weight: 206,19
cis-3-(2-acetoxyphenyl)acrylic acid
Chemical Formula: C11H10O4
Molecular Weight: 206,19
O
HO
22a 17a
 
 
Compound 22a (314 mg, 2.2 mmol) was weight out in a 100 ml round bottomed flask and 
dissolved in methanol (50 ml). The solution was placed under an UV-lamp for irradiation at 
365 nm for 3 days. The solution was then evaporated and the residue was re-dissolved in 
ACN and purified by preparative HPLC with ACN/HCOOH (aq) (25:75) to afford compound 
17a (cis-3-(2-acetoxyphenyl)arylic acid) as a white solid. 
 
YIELD:    40 mg (12.7 %) 
 
HPLC:     Rt: 6.0 minutes (G1) 
 
1H NMR (300 MHz, CD3OD): δ 2.26 (s, 3H), 6.06 (d, 1H, J=12.4Hz), 
    6.88 (d, 1H, J=12.4Hz), 7.08-7.53 (m, 4H) 
     
13C NMR (75 MHz, CD3OD): δ 20.81, 123.29, 124.42, 126.55, 130.14, 130.55,  
    131.25, 136.98, 149.74, 169.85, 170.76  
 
MS (ES+; TOF):   m/z 229.1 ([M+Na]+ = 100 %), 251.1 (23 %) 
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6.6.13  Synthesis of compound 17b,  
cis-3-(2-(propionyloxy)phenyl)acrylic acid [80] 
 
O
O
OH
O
O
O
UV
O
HO
cis-3-(2-(propionyloxy)phenyl)acrylic acid
Chemical Formula: C12H12O4
Molecular Weight: 220,22
trans-3-(2-(propionyloxy)phenyl)acrylic acid
Chemical Formula: C12H12O4
Molecular Weight: 220,22
22b 17b
 
 
Compound 22b (334mg, 1.52 mmol) was weight out in a 100 ml round bottomed flask and 
dissolved in methanol (50 ml). The solution was placed under an UV-lamp for irradiation at 
365 nm for 5 days. The solution was then evaporated and the residue was re-dissolved in 
ACN and purified by preparative HPLC with ACN/HCOOH (aq) (30:70) to afford compound 
17b (cis-3-(2-propionyloxy)phenyl)arylic acid) as a white solid. 
 
YIELD:    69 mg (20.7 %) 
 
HPLC:     Rt: 7.1 minutes (G1) 
 
1H NMR (300 MHz, DMSO): δ 1.13 (t, 3H, J=7.5Hz), 2.58 (q, 2H, J=7.5Hz),  
    6.03 (d, 1H, J=12.4Hz), 6.84 (d, 1H, J=12.4Hz),  
    7.13 (dd, 1H, J=1.1Hz, J=8.1Hz),  
    7.23 (dt, 1H, J=1.0Hz, J=7.5Hz),  
    7.37 (dt, 1H, J=1.6Hz, J=7.7Hz),  
    7.53 (dd, 1H, J=1.4Hz, J=7.7Hz), 12.43 (s, 1H) 
 
13C NMR (75 MHz, DMSO):    δ 8.74, 26.69, 122.19, 123.38, 125.19, 128.25,  
           129.44, 129.87, 134.97, 147.96, 166.77, 171.99  
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6.7 ATTEMPTED SYNTHESIS 
6.7.1 Attempted synthesis of compound 17a,  
(Z)-3-(2-acetoxyphenyl)arylic acid [63] 
O
O O
(Z)-2-(3-oxoprop-1-enyl)phenyl acetate
Chemical Formula: C11H10O3
Molecular Weight: 190,20
H2O2,
NaClO2,
10 oC
O
O
O
HO
(Z)-3-(2-acetoxyphenyl)acrylic acid
Chemical Formula: C11H10O4
Molecular Weight: 206,19
16a 17a
 
 
A solution of 80% sodium chlorite (379 mg, 4.2 mmol) in water (3.35 ml) was added drop 
wise to a stirred mixture of (Z)-2-(3-oxoprop-1-enyl)phenyl acetate (454 mg,  
2.4 mmol) in ACN (2.39 ml), sodium phosphate (77 mg, 0.5 mmol) in water (0.96 ml), and  
30 % hydrogen peroxide (0.28 ml). During the addition, the reaction temperature was kept at 
10 °C with an ice-water bath. Oxygen evolution from the solution was observed visually until 
the end of the reaction. A small amount of sodium sulfite was added to destroy the unreacted 
HOCl and H2O2. The solution was acidified with 1 M HCl to pH 1- 2. The mixture was then 
extracted with ethyl acetate (47 ml). The ethyl acetate layer was washed with saturated 
sodium chloride solution (2 x 18 ml) and dried over Na2SO4 and filtered. The filtrate was 
evaporated and the residue re-dissolved in ACN. The solution was then purified by 
preparative HPLC with ACN/HCOOH (aq) (25:75) to afford a white solid (20 mg).  
 
After analyzing NMR-spectra no reaction product could be detected. 
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6.7.2 Attempted synthesis of compound 15b,  
(Z)-2-(3-hydroxyprop-1-enyl)phenyl propionate [63] 
 
O
O OH
O
O O
TBDMS
H2O:THF:HOAc (1:1:3)
(Z)-2-(3-hydroxyprop-1-enyl)
phenyl propionate
Chemical Formula: C12H14O3
Molecular Weight: 206,24
(Z)-2-(3-(tert-butyldimethylsilyloxy)
prop-1-enyl)phenyl propionate
Chemical Formula: C18H28O3Si
Molecular Weight: 320,50
14b 15b
 
  
To a solution of compound 14b (443 mg, 1.38 mmol) in THF (8 ml) was added water (8 ml). 
This was followed by the drop wise addition of acetic acid (24 ml). The mixture was stirred at 
room temperature for 3 h and then evaporated to remove THF, water and acetic acid. Ethyl 
acetate (15 ml) was added to the residue, which was washed with 5 % NaHCO3 (2 x 8 ml) and 
water (2 x 8 ml). The ethyl acetate solution was dried over Na2SO4, filtered, and evaporated.  
 
The peak for compound 14b in the HPLC chromatogram was gone and analysis of NMR 
spectra could not detect any product. 
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6.7.3 Attempted synthesis of compound 23a,  
(Z)-3-(2-acetoxyphenyl)arylic anhydride 
 
O
O O
O
O
O
HO
O
OO
O
2
DCC
(Z)-3-(2-acetoxyphenyl)acrylic acid
Chemical Formula: C11H10O4
Molecular Weight: 206,19
(Z)-3-(2-acetoxyphenyl)acrylic anhydride
Chemical Formula: C22H18O7
Molecular Weight: 394,37
17a 23a
 
 
A solution of compound 17a ((Z)-3-(2-acetoxyphenyl)arylic acid) (156 mg, 0.8 mmol) in 
DCM (10 ml) was placed on an ice bath. The cold solution was added 
dicyclohexylcarbodiimide (DCC) (78 mg, 0.4 mmol) and stirred for 30 minutes. Then the 
mixture was allowed to warm to room temperature and then stirred for another 24 h.  
 
Method 1: 
The solution was then filtered and carefully evaporated to give a colorless oil. 
 
1H and 13C NMR:   no signal from the product shown 
 
Method 2: 
The solution was then cold down to 0°C and allowed to stir for 30 minutes. The cold solution 
was filtered and carefully evaporated to give a colorless oil. 
 
1H and 13C NMR:   no signal from the product shown 
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6.7.4 Attempted synthesis of compound 23b, 
 (Z)-3-(2-(propionyloxy)phenyl)acrylic anhydride 
 
O
O O
HO
O
O O
O
OO
O
(Z)-3-(2-(propionyloxy)phenyl)acrylic acid
Chemical Formula: C12H12O4
Molecular Weight: 220,22
(Z)-3-(2-(propionyloxy)phenyl)acrylic anhydride
Chemical Formula: C24H22O7
Molecular Weight: 422,43
DCC
2
17b 23b
 
 
A solution of compound 17b ((Z)-3-(2-(propionyloxy)phenyl)arylic acid) (126 mg, 0.572 
mmol) in DCM (10 ml) was placed on an ice bath. The cold solution was added 
dicyclohexylcarbodiimide (DCC) (59 mg, 0.29 mmol) and stirred for 30 minutes. Then the 
mixture was allowed to warm to room temperature and then stirred for another 24 h.  
 
Method 1: 
The solution was then filtered and carefully evaporated to give a colorless oil. 
 
1H and 13C NMR:   no signal from the product shown 
 
Method 2: 
The solution was then cold down to 0°C and allowed to stir for 30 minutes. The cold solution 
was filtered and carefully evaporated to give a colorless oil. 
 
1H and 13C NMR:   no signal from the product shown 
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6.7.5 Attempted synthesis of compound 24b, 
(Z)-2-(3-chloro-3-oxoprop-1-enyl)phenyl propionate 
 
O
O O
HO
O
O O
Cl
Oxalyl dicloride,
DMF
(Z)-3-(2-(propionyloxy)phenyl)acrylic acid
Chemical Formula: C12H12O4
Molecular Weight: 220,22
(Z)-2-(3-chloro-3-oxoprop-1-enyl)phenyl propionate
Chemical Formula: C12H11ClO3
Molecular Weight: 238,67
17b 24b
 
 
To a solution of compound 17b ((Z)-3-(2-(propionyloxy)phenyl)acrylic acid) (51 mg, 0.23 
mmol) in dichloromethane (5 ml) was added 1 droplet of N,N-dimethylformamide (DMF). 
The solution was placed on a magnetic stirrer with a condenser. A surplus of oxalyl chloride 
was drop wise added, approximately 0.5 – 1 ml. Gas evolution of the solution was visually 
observed. The solution was carefully evaporated and analyzed by HPLC. 
 
No peak from the methyl ester of compound 24b observed in the HPLC chromatogram.  
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APPENDIX A  Synthesis from coumarin  
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APPENDIX B  Synthesis from trans-2-hydroxycinnamic acid 
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APPENDIX C Catalytical hydrogenation of an alkyne 
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APPENDIX E  Chemicals and solvents for synthesis 
 
  
Quality Supplier 
  Acetonitrile ≥ 99.9 % Merck 
  Absolutt alkohol prima - Arcus 
  Acetic acid > 90 % Merck 
  Acetic acid anhydride > 98 % KEBO Lab 
  Acetone > 99.5 % Merck 
  Ammonium acetate ≥ 96 % BDH Laboratory chemicals 
  Coumarin - Sigma 
  Dichloromethane > 99.9 % Fluka, Riedel-de Häen 
  N,N-dicyclohexylcarbodiimide  ~ 99 % Fluka 
  Diethyl ether min 99.5 % Riedel-de Häen 
  N,N-Dimethylformamide ≥ 99.8 % Fluka, Riedel-de Häen 
  N,N-Dimethylpyridin-4-amine ≥ 98 % Fluka 
  Ethyl acetate > 99.5 % Fluka 
  Formic acid 98-100 % Merck 
  Hydrochloric acid 32 % min 32 % Riedel-de Häen 
  Hydrogen peroxide 30% ≥ 30 % Fluka 
  Hydroxylamine Solution ~ 50 % Fluka 
  Isopropanol - A/S Vinmonopolet 
  Lithium aluminum hydride solution - Aldrich 
  Magnesium sulfate anhydrous ≥ 98 % Fluka 
  Methanol min 99.9 % Sigma-Aldrich 
  Oxalyl chloride ~ 98 % Fluka 
  Propionic anhydride ~ 98 % Fluka 
  Pyridine ≥ 99.8 % Fluka 
  Pyridinium chlorochromate ≥ 98 % Fluka 
  Sodium bicarbonate ≥ 99.5 % Aldrich 
  Sodium carbonate - KEBO Lab 
  Sodium chlorite 80 % Fluka 
  Sodium phosphate 96 % Aldrich 
  Sodium sulfite - KEBO Lab 
  Sodium sulphate ≥ 99.0 % Fluka 
  tert-Butyl-dimethylsilylchlorid 97 % Aldrich 
  Tetrahydrofuran min 99.9 % Sigma-Aldrich 
  Tetrahydrofuran, anhydrous ≥ 99.9 % Fluka 
  trans-O-coumaric acid >98 % TCI Europe 
  Triethylamine 98 % Fluka 
 
